<?xml version="1.0" ?>
<document version="1.8" entity_encoding="single">
  <page number="1">
    <text>HAEMATOLOGY
AND DENTISTRY 2:
IMMUNOCOMPROMISE (WBC) AND HAEMATOLOGICAL
MALIGNANCIES

2026 DMD3 DENT5311 – Integrated Dental Practice 2 (Special Needs Dentistry)

Dr Jee-Yun Leung *BDSc(Hons) MSc(SCD) DSCD(RCSEng) DClinDent(SND) MRACDS(SND)*</text>
    <formatted_text>Immunocompromise (WBC) and Haematological Malignancies

2026 DMD3 DENT5311 – Integrated Dental Practice 2 (Special Needs Dentistry)

Dr Jee-Yun Leung *BDSc(Hons) MSc(SCD) DSCD(RCSEng) DClinDent(SND) MRACDS(SND)*</formatted_text>
  </page>
  <page number="2">
    <text>LECTURE
OUTCOMES

1. Review the role of WBCs, systemic disorders and treatments which affect their structure and function, and general management

2. Review the oral manifestations of disorders of WBCs

3. Risk assess the implications of WBC disorders, and the treatment modifications required, when planning dental procedures</text>
    <formatted_text>1. Review the role of WBCs, systemic disorders and treatments which affect their structure and function, and general management

2. Review the oral manifestations of disorders of WBCs

3. Risk assess the implications of WBC disorders, and the treatment modifications required, when planning dental procedures</formatted_text>
    <images>
      <img order="0" bbox="470,175,972,825" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A decorative 3D abstract illustration showing a stylized white figure composed of stacked geometric shapes (a sphere, a curved form, and a cone) sitting in the center of concentric ripples.</description>
      </img>
    </images>
  </page>
  <page number="3">
    <text>WHITE CELL DISORDERS

*   Non-neoplastic disorders of white cells
    *   Leukopenia
    *   Reactive Leukocytosis
    *   Reactive Lymphadenitis
*   Neoplastic proliferations of white cells
    *   *Leukaemias
    *   *Myelodysplastic syndromes
    *   *Myeloproliferative neoplasms
    *   *Lymphomas: Hodgkin’s and Non-Hodgkin’s
    *   *Plasma cell neoplasms (e.g. multiple myeloma)
    *   Histiocytic neoplasms
    *   Post-transplant lymphoproliferative disorder

Adapted from Robins Basic Pathology ed11 2023 (Kumar, Abbas, Aster, Robbins)</text>
    <formatted_text>- Non-neoplastic disorders of white cells
  - Leukopenia
  - Reactive Leukocytosis
  - Reactive Lymphadenitis
- Neoplastic proliferations of white cells
  - Leukaemias
  - Myelodysplastic syndromes
  - Myeloproliferative neoplasms
  - Lymphomas: Hodgkin's and Non-Hodgkin's
  - Plasma cell neoplasms (e.g. multiple myeloma)
  - Histiocytic neoplasms
  - Post-transplant lymphoproliferative disorder

*Adapted from Robins Basic Pathology ed11 2023 (Kumar, Abbas, Aster, Robbins)*</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:02:25" confidence="5" anchor="- Post-transplant lymphoproliferative disorder  *Adapted from Robins Basic Patho">

&gt; [!note] Lecturer — White Cell Disorders
&gt; White-cell disorders may involve deficiencies, but proliferations or excess cells are more common.
&gt;
&gt; - The lecture focused mainly on neoplastic proliferations.
</insert>
      <insert timestamp="00:03:42" confidence="10" anchor="#### **Primary Lymphoid Organs**  - Thymus - Bone marrow  #### **Secondary Lymph">

&gt; [!note] Lecturer — Lymphatic System
&gt; The lymphatic system collects excess fluid from tissues, returns it to the venous circulation, circulates lymphocytes, and contributes to adaptive, lymphocyte-mediated immunity.
&gt;
&gt; - It is therefore part of both the circulatory system and the immune system.
</insert>
      <insert timestamp="00:04:25" confidence="6" anchor="#### **Non-palpable Nodes**  - Mediastinal   - Retrocrural - Para-aortic   - Com">

&gt; [!note] Lecturer — Lymph Node Examination
&gt; Cervical lymph nodes are routinely assessed during extraoral examination. Other lymph-node clusters are distributed throughout the body and may not be palpable during routine dental examination.
</insert>
    </audio_inserts>
  </page>
  <page number="4">
    <text>FORMATION OF BLOOD CELLS

**Adapted from Kumar and Clark’s Clinical Medicine (11th ed, 2025)**

Haemopoietic stem cell
Common myeloid progenitor
Common lymphoid progenitor
Megakaryocyte erythroid progenitor
Granulocyte macrophage progenitor
Thymus
Megakaryocyte
Erythroblast
B cell progenitor
T cell progenitor
Platelet
Erythrocyte
Neutrophil
Eosinophil
Basophil
Dendritic cell
B cell
T cell
NK cell

![](L5.2 Haematology 2 WBC_figures/img_90ca14c2724d8efa.webp)</text>
    <formatted_text>*Adapted from Kumar and Clark's Clinical Medicine (11th ed, 2025)*

#### Haemopoietic Cell Lineage

- Haemopoietic stem cell
  - Common myeloid progenitor
    - Megakaryocyte erythroid progenitor
      - Megakaryocyte → Platelet
      - Erythroblast → Erythrocyte
    - Granulocyte macrophage progenitor
      - Neutrophil
      - Eosinophil
      - Basophil
      - Dendritic cell
  - Common lymphoid progenitor
    - B cell progenitor → B cell
    - T cell progenitor (thymus) → T cell
    - NK cell</formatted_text>
    <images>
      <img order="0" bbox="113,269,884,833" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_90ca14c2724d8efa.webp">
        <description>A hierarchical flowchart illustrating the process of haemopoiesis, showing the lineage progression from a central Haemopoietic stem cell. The diagram branches into Common myeloid and lymphoid progenitors, further differentiating into specific cell types such as Platelets, Erythrocytes, Neutrophils, B cells, and T cells.</description>
      </img>
    </images>
  </page>
  <page number="5">
    <text>LYMPHOID ORGANS

Primary lymphoid organs
Thymus
Bone marrow

Secondary lymphoid organs
Pharyngeal and palatine tonsils
Lymph nodes
Spleen
Peyer’s patches
Appendix

![](L5.2 Haematology 2 WBC_figures/img_11e91fa959e06f09.webp)</text>
    <formatted_text>#### Primary Lymphoid Organs

- Thymus
- Bone marrow

#### Secondary Lymphoid Organs

- Pharyngeal and palatine tonsils
- Lymph nodes
- Spleen
- Peyer's patches
- Appendix</formatted_text>
    <images>
      <img order="0" bbox="286,291,744,824" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_11e91fa959e06f09.webp">
        <description>Labelled anatomical diagram showing the locations of primary and secondary lymphoid organs within a human silhouette. Specific structures identified by leader lines include the Thymus, Bone marrow, Pharyngeal and palatine tonsils, Lymph nodes (depicted as red dots), Spleen, Peyer's patches, and Appendix.</description>
      </img>
    </images>
  </page>
  <page number="6">
    <text>LYMPH NODE GROUPS

Cervical
Posterior cervical

Mediastinal
Paratracheal
Mediastinal
Hilar
Retrocrural

Epitrochlear
Epitrochlear

Para-aortic
Para-aortic
Common iliac
External iliac

Cervical
Pre-auricular
Upper cervical
Median or lower cervical
Supraclavicular

Axillary
Axillary

Mesenteric
Celiac
Splenic hilar
Portal
Mesenteric

Inguinal
Inguinal
Femoral

Popliteal
Popliteal

Palpable nodes
Non-palpable nodes

![](L5.2 Haematology 2 WBC_figures/img_e4491dd2ebdebac2.webp)</text>
    <formatted_text>#### Palpable Nodes

- Cervical
  - Pre-auricular
  - Upper cervical
  - Median or lower cervical
  - Posterior cervical
- Mediastinal
  - Paratracheal
  - Hilar
- Epitrochlear
- Axillary
- Inguinal
  - Femoral
- Popliteal

#### Non-palpable Nodes

- Mediastinal
  - Retrocrural
- Para-aortic
  - Common iliac
  - External iliac
- Mesenteric
  - Celiac
  - Splenic hilar
  - Portal</formatted_text>
    <images>
      <img order="0" bbox="498,206,943,795" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_e4491dd2ebdebac2.webp">
        <description>An anatomical diagram of the anterior human torso and neck illustrating the distribution of major lymph node groups. Green solid circles represent palpable nodes (located at cervical, axillary, epitrochlear, inguinal, femoral, and popliteal sites), while white open circles represent non-palpable nodes (located in mediastinal, para-aortic, iliac, and mesenteric regions). Leader lines connect specific clusters of these nodes to text boxes on either side that name the corresponding anatomical groups.</description>
      </img>
    </images>
  </page>
  <page number="7">
    <text>NON-NEOPLASTIC
DISORDERS OF
WHITE CELLS</text>
    <formatted_text>Non-neoplastic disorders of white cells</formatted_text>
  </page>
  <page number="8">
    <text># NON-NEOPLASTIC DISORDERS OF WHITE CELLS

*   **Leukopenia**
    *   Most commonly due to neutropenia (reduced granulocyte count)
        *   Agranulocytosis: severe reduction in granulocyte count
        *   Mechanisms:
            *   Decreased granulocyte production: marrow hypoplasia (chemo, aplastic anaemia), certain drugs
            *   Increased granulocyte destruction: immune-mediated injury (e.g. drugs), overwhelming infections (increased peripheral “use”), sequestration from splenomegaly
    *   Lymphopenia: less common – rare congenital immunodeficiency diseases, advanced HIV infection, high dose corticosteroids

*   **Reactive Leukocytosis**
    *   Inflammatory states caused by microbial and nonmicrobial stimuli
    *   Infectious mononucleosis $\rightarrow$ lymphocytosis

*   **Reactive Lymphadenitis**
    *   Infections and nonmicrobial inflammatory stimuli activate immune cells residing in lymph nodes $\rightarrow$ lymphadenopathy</text>
    <formatted_text>#### Leukopenia

- Most commonly due to neutropenia (reduced granulocyte count)
  - Agranulocytosis: severe reduction in granulocyte count
  - Mechanisms:
    - Decreased granulocyte production: marrow hypoplasia (chemo, aplastic anaemia), certain drugs
    - Increased granulocyte destruction: immune-mediated injury (e.g. drugs), overwhelming infections (increased peripheral &quot;use&quot;), sequestration from splenomegaly
- Lymphopenia: less common — rare congenital immunodeficiency diseases, advanced HIV infection, high dose corticosteroids

#### Reactive Leukocytosis

- Inflammatory states caused by microbial and nonmicrobial stimuli
- Infectious mononucleosis → lymphocytosis

#### Reactive Lymphadenitis

- Infections and nonmicrobial inflammatory stimuli activate immune cells residing in lymph nodes → lymphadenopathy</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:04:43" confidence="6" anchor="Lymphopenia: less common — rare congenital immunodeficiency diseases, advanced H">
- ==Granulocytes are the most numerous circulating white cells.==</insert>
      <insert timestamp="00:05:14" confidence="4" anchor="Inflammatory states caused by microbial and nonmicrobial stimuli Infectious mono">
- ==Reactive leukocytosis is an increased number of white cells in the blood.==</insert>
      <insert timestamp="00:05:48" confidence="8" anchor="Infections and nonmicrobial inflammatory stimuli activate immune cells residing ">
- ==Lymph nodes act as defence barriers.==
- ==Infections causing lymphadenitis are varied and numerous and may be acute or chronic.==</insert>
    </audio_inserts>
  </page>
  <page number="9">
    <text/>
  </page>
  <page number="10">
    <text>CLASSIFICATION SYSTEMS

WHO (World Health Organisation) -Very comprehensive

FAB (French American British) – Myeloproliferative disorders

**WHO 2008**
**WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues**

**French American British (FAB)**
**1976 &amp; 1982**

British Journal of Haematology, 1976, 33, 451.
Proposals for the Classification of the Acute Leukaemias
FRENCH-AMERICAN-BRITISH (FAB) CO-OPERATIVE GROUP
J. M. BENNETT,* D. CATOVSKY,† MARIE-THÉRÈSE DANIEL,‡ G. FLANDRIN,‡
D. A. G. GALTON,† H. R. GRAINICK§ AND C. SULTAN¶
*University of Rochester Cancer Centre, University of Rochester School of Medicine and Dentistry, Rochester, New York, U.S.A., †M.R.C. Leukaemia Unit, Royal Postgraduate Medical School, London, ‡Institut de Recherchés sur les Leucémies et les Maladies du Sang, Hopital Saint-Louis, Paris, France, §Hematology Service, National Institutes of Health, Bethesda, Maryland, U.S.A., ¶Service Central d'Hématologie-Immunologie, Hôpital Henri Mondor, Creteil, France
(Received 23 January 1976; accepted for publication 26 January 1976)

British Journal of Haematology, 1982, 51, 189–199
Proposals for the classification
of the myelodysplastic syndromes
J. M. BENNETT,¹ D. CATOVSKY,² M. T. DANIEL,³ G. FLANDRIN,⁴ D. A. G. GALTON,⁵ H. R. GRAINICK⁶ AND C. SULTAN,⁷ THE FRENCH-AMERICAN-BRITISH (FAB) CO-OPERATIVE GROUP ¹University of Rochester Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, U.S.A., ²MRC Leukaemia Unit, Royal Postgraduate Medical School, London, ³Institut de Recherches sur les Leucémi-, et les Maladies du Sang, Hôpital Saint-Louis, Paris, France, ⁴Hematology Service, National Institutes of Health, Bethesda, Maryland, U.S.A., and ⁵Service Central d’Hématologie-Immunologie, Hôpital Henri Mondor, Creteil, France
Received 12 November 1981; accepted for publication 18 December 1981

![WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues](L5.2 Haematology 2 WBC_figures/img_29fbed7c685fec28.webp)</text>
    <formatted_text>- **WHO** (World Health Organisation) — very comprehensive
- **FAB** (French American British) — myeloproliferative disorders

#### WHO 2008

*WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*

#### French American British (FAB) — 1976 &amp; 1982

*British Journal of Haematology, 1976, 33, 451. Proposals for the Classification of the Acute Leukaemias. French-American-British (FAB) Co-operative Group. J. M. Bennett, D. Catovsky, Marie-Thérèse Daniel, G. Flandrin, D. A. G. Galton, H. R. Grainick and C. Sultan. (Received 23 January 1976; accepted for publication 26 January 1976)*

*British Journal of Haematology, 1982, 51, 189–199. Proposals for the classification of the myelodysplastic syndromes. J. M. Bennett, D. Catovsky, M. T. Daniel, G. Flandrin, D. A. G. Galton, H. R. Grainick and C. Sultan, The French-American-British (FAB) Co-operative Group. (Received 12 November 1981; accepted for publication 18 December 1981)*</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:06:08" confidence="3" anchor="- **FAB** (French American British) — myeloproliferative disorders">

&gt; [!note] Lecturer — Classification Scope
&gt; These classification systems were introduced for awareness rather than detailed memorisation. The WHO system is used for malignant disorders of white cells.
</insert>
      <insert timestamp="00:31:57" confidence="3" anchor="*British Journal of Haematology, 1982, 51, 189–199. Proposals for the classifica">
- ==Chronic myelomonocytic leukaemia was referenced in relation to oral manifestations== as a subtype of myelodysplastic syndrome.</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="360,395,594,785" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L5.2 Haematology 2 WBC_figures/img_29fbed7c685fec28.webp" caption="WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues">
        <description>This figure displays the front cover of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues book. The design features a grid of nine diagnostic images representing various classification modalities, including gross pathology specimens (such as bone marrow and lymph nodes), microscopic cytology slides, flow cytometry plots, and genetic analysis visuals like karyotypes and FISH.</description>
      </img>
    </images>
  </page>
  <page number="11">
    <text>CLASSIFICATION SYSTEMS

**Revised European &amp; American Lymphoma (REAL) 1994**

**European Organisation for Research and Treatment of Cancer (EORTC) 1997**

REAL (Revised European and American Lymphoma) – Lymphomas

EORTC (European Organisation for Research and Treatment of Cancer) -Lymphoma</text>
    <formatted_text>- **REAL** (Revised European and American Lymphoma), 1994 — lymphomas
- **EORTC** (European Organisation for Research and Treatment of Cancer), 1997 — lymphoma</formatted_text>
  </page>
  <page number="12">
    <text>**COMMON HAEMATOLOGICAL MALIGNANCIES**

1. Leukaemias
2. Lymphomas
   a) Hodgkin’s lymphoma
   b) Non-Hodgkin’s lymphomas
3. Myelodysplastic syndromes
4. [Non-leukaemic] Myeloproliferative neoplasms
5. Plasma cell tumours</text>
    <formatted_text>1. Leukaemias
2. Lymphomas
   - Hodgkin's lymphoma
   - Non-Hodgkin's lymphomas
3. Myelodysplastic syndromes
4. [Non-leukaemic] Myeloproliferative neoplasms
5. Plasma cell tumours</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:42:18" confidence="2" anchor="5. Plasma cell tumours">
    - ==Particularly multiple myeloma==</insert>
      <insert timestamp="00:14:03" confidence="4" anchor="- Oral ulceration">
- ==In congenital disorders, AML may develop during childhood or adolescence.==</insert>
    </audio_inserts>
  </page>
  <page number="13">
    <text/>
  </page>
  <page number="14">
    <text>LEUKAEMIAS

• Definition: Malignant neoplasms of haematopoietic tissue that progressively displaces normal blood forming elements of bone marrow with neoplastic cells

• Classification: on basis of cell type and maturity
  • Lymphoid or myeloid
  • Acute or chronic
    • Acute: &gt;20% myeloblasts or lymphoblasts in bone marrow at clinical pres
    • Chronic: cells more differentiated

![Leukaemia, Acute, Chronic, Lymphoid (ALL), Myeloid (AML), Lymphoid (CLL), Myeloid (CML)](L5.2 Haematology 2 WBC_figures/img_b7b1882cad73d6ee.webp)</text>
    <formatted_text>- **Definition:** Malignant neoplasms of haematopoietic tissue that progressively displace normal blood-forming elements of bone marrow with neoplastic cells

- **Classification:** on basis of cell type and maturity
  - Lymphoid or myeloid
  - Acute or chronic
    - Acute: &gt;20% myeloblasts or lymphoblasts in bone marrow at clinical presentation
    - Chronic: cells more differentiated</formatted_text>
    <images>
      <img order="0" bbox="546,587,949,806" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_b7b1882cad73d6ee.webp" caption="Leukaemia, Acute, Chronic, Lymphoid (ALL), Myeloid (AML), Lymphoid (CLL), Myeloid (CML)">
        <description>A hierarchical flowchart classifying Leukaemia into two main branches, Acute and Chronic. Each branch is further subdivided by cell type into Lymphoid (ALL for acute, CLL for chronic) and Myeloid (AML for acute, CML for chronic).</description>
      </img>
    </images>
  </page>
  <page number="15">
    <text>LEUKAEMIAS

• Main types of leukaemia:
• Acute lymphoblastic leukaemia (ALL): most common type of childhood leukaemia
• Acute myeloblastic leukaemia (AML): can occur at any age, more often older people
• Chronic lymphocytic leukaemia (CLL): most common type of leukaemia in adults. Slow-growing, may be asymptomatic for months-years.
• Chronic myeloid leukaemia (CML): mostly affects adults &gt;40yo. Progresses over weeks or months.

![](L5.2 Haematology 2 WBC_figures/img_ea99b5ec222e9f98.webp)</text>
    <formatted_text>Main types of leukaemia:

- **Acute lymphoblastic leukaemia (ALL):** most common type of childhood leukaemia
- **Acute myeloblastic leukaemia (AML):** can occur at any age, more often older people
- **Chronic lymphocytic leukaemia (CLL):** most common type of leukaemia in adults. Slow-growing, may be asymptomatic for months–years.
- **Chronic myeloid leukaemia (CML):** mostly affects adults &gt;40 years old. Progresses over weeks or months.</formatted_text>
    <images>
      <img order="0" bbox="270,610,672,826" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_ea99b5ec222e9f98.webp">
        <description>A hierarchical flowchart classifying Leukaemia into two main branches: Acute and Chronic. The Acute branch is further subdivided into Lymphoid (ALL) and Myeloid (AML), while the Chronic branch is subdivided into Lymphoid (CLL) and Myeloid (CML).</description>
      </img>
    </images>
  </page>
  <page number="16">
    <text>&lt;h2&gt;ACUTE VS CHRONIC LEUKAEMIA&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Acute&lt;/th&gt;
    &lt;th&gt;Chronic&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Cell Type&lt;/td&gt;
    &lt;td&gt;Primitive (immature) blast cells in blood and bone marrow&lt;/td&gt;
    &lt;td&gt;Excess mature leukocytes in blood and bone marrow&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Epidemiology&lt;/td&gt;
    &lt;td&gt;50% of all malignancies in children&lt;/td&gt;
    &lt;td&gt;Mostly adults&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Symptoms&lt;/td&gt;
    &lt;td&gt;Develop quickly&lt;/td&gt;
    &lt;td&gt;Develop gradually (20% have no symptoms at time of diagnosis), may progress to acute leukaemia&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L5.2 Haematology 2 WBC_figures/img_148fd788d64b1420.webp)</text>
    <formatted_text>| | Acute | Chronic |
| :--- | :--- | :--- |
| Cell Type | Primitive (immature) blast cells in blood and bone marrow | Excess mature leukocytes in blood and bone marrow |
| Epidemiology | 50% of all malignancies in children | Mostly adults |
| Symptoms | Develop quickly | Develop gradually (20% have no symptoms at time of diagnosis), may progress to acute leukaemia |</formatted_text>
    <images>
      <img order="0" bbox="122,351,877,744" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_148fd788d64b1420.webp">
        <description>A comparison table contrasting Acute and Chronic Leukaemia across three specific criteria: Cell Type, Epidemiology, and Symptoms. The rows detail differences in cell maturity (primitive blasts vs. excess mature leukocytes), patient demographics (children vs. adults), and disease progression speed.</description>
      </img>
    </images>
  </page>
  <page number="17">
    <text>ACUTE LEUKAEMIA

Clinical features
Associated with:
• Bone marrow failure
• Tissue infiltration

| Anaemia | Neutropenia | Thrombocytopenia |
| :--- | :--- | :--- |
| Fatigue | Infections | Bleeding |
| Breathlessness | Fever | Bruising |
| Pallor | Oral ulceration | Gingival bleeding |

![](L5.2 Haematology 2 WBC_figures/img_0ba98e9e331654f3.webp)</text>
    <formatted_text>Clinical features associated with:

- Bone marrow failure
- Tissue infiltration

#### Bone Marrow Failure

| Anaemia | Neutropenia | Thrombocytopenia |
| :--- | :--- | :--- |
| Fatigue | Infections | Bleeding |
| Breathlessness | Fever | Bruising |
| Pallor | Oral ulceration | Gingival bleeding |</formatted_text>
    <images>
      <img order="0" bbox="287,433,951,589" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_0ba98e9e331654f3.webp">
        <description>A three-column table listing clinical features associated with acute leukaemia, categorized under the headings Anaemia, Neutropenia, and Thrombocytopenia. Each column details specific symptoms such as fatigue, infections, and bleeding respectively.</description>
      </img>
    </images>
  </page>
  <page number="18">
    <text>ACUTE LEUKAEMIA

Clinical features
Associated with:
• Bone marrow failure
• Tissue infiltration

| Tissue infiltration | Features |
| :--- | :--- |
| Marrow | Bone pain |
| Lymph nodes | Lymphadenopathy |
| Liver/spleen | Hepatosplenomegaly |
| Gingiva | Gingival hypertrophy (AML) |
| Skin | Violaceous skin deposits (AML) |
| CNS | Headache, CN palsy (ALL) |
| Testes | Enlargement (ALL) |

DermNet NZ
https://dermnetnz.org/topics/leukaemia-cutis

![Gingival hypertrophy associated with AML](L5.2 Haematology 2 WBC_figures/img_908a830caa5df6e8.webp)
![](L5.2 Haematology 2 WBC_figures/img_105e28e2d9ec05ac.webp)
![](L5.2 Haematology 2 WBC_figures/img_51ad6b60642ec407.webp)</text>
    <formatted_text>Clinical features associated with:

- Bone marrow failure
- Tissue infiltration

#### Tissue Infiltration

| Tissue infiltration | Features |
| :--- | :--- |
| Marrow | Bone pain |
| Lymph nodes | Lymphadenopathy |
| Liver/spleen | Hepatosplenomegaly |
| Gingiva | Gingival hypertrophy (AML) |
| Skin | Violaceous skin deposits (AML) |
| CNS | Headache, CN palsy (ALL) |
| Testes | Enlargement (ALL) |

*DermNet NZ — https://dermnetnz.org/topics/leukaemia-cutis*</formatted_text>
    <images>
      <img order="0" bbox="713,152,928,347" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_908a830caa5df6e8.webp" caption="Gingival hypertrophy associated with AML">
        <description>Clinical photograph showing the anterior maxillary region of a patient with significant gingival hypertrophy. The gum tissue is markedly swollen, red, and bulbous, extending downwards to partially cover the crowns of the upper teeth.</description>
      </img>
      <img order="1" bbox="93,616,281,798" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_105e28e2d9ec05ac.webp">
        <description>Clinical photo: Shows a close-up of skin on an extremity with multiple scattered, reddish-purple papules and nodules. This visual presentation illustrates the 'Violaceous skin deposits' associated with tissue infiltration in acute leukaemia.</description>
      </img>
      <img order="2" bbox="365,370,951,837" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_51ad6b60642ec407.webp">
        <description>A two-column table titled 'Tissue infiltration' and 'Features'. It lists specific tissues (Marrow, Lymph nodes, Liver/spleen, Gingiva, Skin, CNS, Testes) alongside their associated clinical features in acute leukaemia (e.g., Bone pain, Lymphadenopathy, Hepatosplenomegaly).</description>
      </img>
    </images>
  </page>
  <page number="19">
    <text># ACUTE LYMPHOBLASTIC LEUKAEMIA

• 65% of childhood acute leukaemia (most common leukaemia in children)
• Predominantly children (peak incidence 0-4yo), but can affect adults
• Risk factors:
    • Some congenital disorders: Down Syndrome (33-fold ↑ risk), Fanconi’s anaemia
    • Philadelphia chromosome (25% adult cases, 3-5% of children)
    • Exposure to radiation, chemicals, reaction to viral infections</text>
    <formatted_text>- 65% of childhood acute leukaemia (most common leukaemia in children)
- Predominantly children (peak incidence 0–4 years old), but can affect adults
- Risk factors:
  - Some congenital disorders: Down Syndrome (33-fold ↑ risk), Fanconi's anaemia
  - Philadelphia chromosome (25% adult cases, 3–5% of children)
  - Exposure to radiation, chemicals, reaction to viral infections</formatted_text>
  </page>
  <page number="20">
    <text>ACUTE LYMPHOBLASTIC
LEUKAEMIA

• Features
  • CNS involvement (cranial nerve palsies, sensory disturbances)
  • Testes enlargement
  • Pain in bone/joints

  • Acute serious illness, infections
  • Purpura
  • Gingival bleeding on brushing

  • Bilateral salivary +/- lacrimal gland swelling (Mikulicz syndrome)

![](L5.2 Haematology 2 WBC_figures/img_6e79d052b9716f97.webp)</text>
    <formatted_text>#### Features

- CNS involvement (cranial nerve palsies, sensory disturbances)
- Testes enlargement
- Pain in bone/joints
- Acute serious illness, infections
- Purpura
- Gingival bleeding on brushing
- Bilateral salivary ± lacrimal gland swelling (Mikulicz syndrome)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:31:57" confidence="2" anchor="- Gingival bleeding">
- ==Oral ulceration==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="618,354,914,742" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_6e79d052b9716f97.webp">
        <description>Clinical photo: A four-panel composite showing patients with significant bilateral or unilateral facial swelling, particularly affecting the periorbital region and cheeks. The images illustrate severe soft tissue enlargement, consistent with the features of acute leukaemia such as salivary gland involvement.</description>
      </img>
    </images>
  </page>
  <page number="21">
    <text>ACUTE LYMPHOBLASTIC
LEUKAEMIA

• Prognosis
    • Complete remission / 5-year survival = 70–80% (combined children and adult)
        • &lt;15 years old: 90%
        • 15–40 years old: 65%
        • &gt;40 years old: 25%</text>
    <formatted_text>#### Prognosis

- Complete remission / 5-year survival = 70–80% (combined children and adult)
  - &lt;15 years old: 90%
  - 15–40 years old: 65%
  - &gt;40 years old: 25%</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:12:24" confidence="7" anchor="- &gt;40 years old: 25%">

&gt; [!note] Lecturer — ALL Prognosis
&gt; Prognosis influences dental treatment planning.
&gt;
&gt; - A favourable long-term prognosis may support comprehensive treatment.
&gt; - A poor prognosis may support a more palliative or symptom-focused approach.
</insert>
    </audio_inserts>
  </page>
  <page number="22">
    <text>ACUTE MYELOBLASTIC LEUKAEMIA

• Most common acute leukaemia in adults (especially males)
• Peak incidence older age (60-70yo)
• Risk factors:
    • Some congenital disorders: Down Syndrome (150-fold ↑ risk), Fanconi’s anaemia, Boom syndrome
    • Some blood disorders: myelodysplastic syndromes and myelofibrosis, aplastic anaemia, paroxysmal nocturnal haemoglobinuria
    • Exposure to radiation, chemicals, chemotherapy, tobacco</text>
    <formatted_text>- Most common acute leukaemia in adults (especially males)
- Peak incidence older age (60–70 years old)
- Risk factors:
  - Some congenital disorders: Down Syndrome (150-fold ↑ risk), Fanconi's anaemia, Bloom syndrome
  - Some blood disorders: myelodysplastic syndromes and myelofibrosis, aplastic anaemia, paroxysmal nocturnal haemoglobinuria
  - Exposure to radiation, chemicals, chemotherapy, tobacco</formatted_text>
  </page>
  <page number="23">
    <text>ACUTE MYELOBLASTIC LEUKAEMIA

*   Features
    *   Violaceous skin deposits

Violaceous skin deposits
Gingival hypertrophy
Neutropenic ulceration

| Primary (direct infiltration) | Secondary (blood and immune changes) |
| :--- | :--- |
| Gingival enlargement (hypertrophy) | Mucosal pallor |
| Bone infiltration | Anaemia-related lesions |
| - Tooth mobility | Neutropenic ulceration |
| - Neuropathy | Susceptible to infection |
| - Jaw discomfort | Gingival bleeding |

![](L5.2 Haematology 2 WBC_figures/img_570eb9d8892933fa.webp)
![](L5.2 Haematology 2 WBC_figures/img_a62b78069e7d9f7c.webp)
![](L5.2 Haematology 2 WBC_figures/img_313e9a196695ae10.webp)
![](L5.2 Haematology 2 WBC_figures/img_7ec2a161b107f95f.webp)</text>
    <formatted_text>#### Features

- Violaceous skin deposits
- Gingival hypertrophy
- Neutropenic ulceration

| Primary (direct infiltration) | Secondary (blood and immune changes) |
| :--- | :--- |
| Gingival enlargement (hypertrophy) | Mucosal pallor |
| Bone infiltration | Anaemia-related lesions |
| - Tooth mobility | Neutropenic ulceration |
| - Neuropathy | Susceptible to infection |
| - Jaw discomfort | Gingival bleeding |</formatted_text>
    <images>
      <img order="0" bbox="71,481,598,792" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_570eb9d8892933fa.webp">
        <description>A two-column table comparing 'Primary (direct infiltration)' features with 'Secondary (blood and immune changes)' features. The left column lists gingival enlargement, bone infiltration (with sub-points for tooth mobility, neuropathy, and jaw discomfort), while the right column lists mucosal pallor, anaemia-related lesions, neutropenic ulceration, susceptibility to infection, and gingival bleeding.</description>
      </img>
      <img order="1" bbox="692,329,903,548" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_a62b78069e7d9f7c.webp">
        <description>Clinical photo: This image shows a patient's upper back and shoulder area covered in numerous discrete, violaceous (purplish-red) skin nodules and papules. These lesions are consistent with the 'violaceous skin deposits' mentioned in the slide text as a feature of acute myeloblastic leukaemia.</description>
      </img>
      <img order="2" bbox="612,571,798,746" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_313e9a196695ae10.webp">
        <description>Clinical photo: Close-up view of the upper anterior teeth and gums showing significant gingival enlargement (hypertrophy), where the swollen gum tissue covers a large portion of the tooth crowns.</description>
      </img>
      <img order="3" bbox="811,572,944,746" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_7ec2a161b107f95f.webp">
        <description>Clinical photo: An intraoral close-up showing the gingival tissue adjacent to a tooth. The gum appears swollen and reddish-purple, illustrating the condition of gingival hypertrophy (or enlargement) mentioned in the slide text.</description>
      </img>
    </images>
  </page>
  <page number="24">
    <text>ACUTE MYELOBLASTIC LEUKAEMIA

• Prognosis
  • 5-year survival
    • &lt;40yo: 55%
    • 40-49yo: 50%
    • 50-59yo: 25%
    • 60-69yo: 15%
    • 70-79yo: 5%
    • &gt;80yo: 1%</text>
    <formatted_text>#### Prognosis

5-year survival:

- &lt;40 years old: 55%
- 40–49 years old: 50%
- 50–59 years old: 25%
- 60–69 years old: 15%
- 70–79 years old: 5%
- &gt;80 years old: 1%</formatted_text>
  </page>
  <page number="25">
    <text># CHRONIC LYMPHOCYTIC LEUKAEMIA

*   Overpopulation of lymphocytes (B-cells) in blood and bone marrow
    *   Shared features with small lymphocytic lymphoma (but cancer cells in lymph nodes)
*   Most common type of leukaemia in adults
    *   2x as common as CML
    *   25% of all leukaemias
*   Median age diagnosis 65yo (mostly older adults)
*   Risk factors:
    *   Gender – M:F = 2:1
    *   Ethnicity = white European origin
    *   Family history = 10% have parent, sibling, child
    *   Exposure to high-risk chemicals e.g. pesticides, benzene, heavy solvents</text>
    <formatted_text>- Overpopulation of lymphocytes (B-cells) in blood and bone marrow
  - Shared features with small lymphocytic lymphoma (but cancer cells in lymph nodes)
- Most common type of leukaemia in adults
  - 2× as common as CML
  - 25% of all leukaemias
- Median age at diagnosis 65 years old (mostly older adults)
- Risk factors:
  - Gender – M:F = 2:1
  - Ethnicity = white European origin
  - Family history = 10% have parent, sibling, child affected
  - Exposure to high-risk chemicals e.g. pesticides, benzene, heavy solvents</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:16:07" confidence="8" anchor="- Overpopulation of lymphocytes (B-cells) in blood and bone marrow   - Shared fe">

&gt; [!note] Lecturer — CLL Classification
&gt; The WHO classifies chronic lymphocytic leukaemia as a slow-growing non-Hodgkin lymphoma because it affects lymphocytes. It is traditionally called leukaemia because the malignant cells mainly accumulate in the blood and bone marrow.
</insert>
    </audio_inserts>
  </page>
  <page number="26">
    <text># CHRONIC LYMPHOCYTIC LEUKAEMIA

*   Features
    *   Often asymptomatic (1/3 diagnosed following routine FBC)
    *   Recurrent/severe infections (e.g. shingles)
    *   Painless lymphadenopathy

*   Anaemia
*   Fever
*   Splenomegaly
*   Thrombocytopenia</text>
    <formatted_text>#### Features

- Often asymptomatic (1/3 diagnosed following routine FBC)
- Recurrent/severe infections (e.g. shingles)
- Painless lymphadenopathy
- Anaemia
- Fever
- Splenomegaly
- Thrombocytopenia</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:17:30" confidence="7" anchor="- Thrombocytopenia">
- ==Gingival or palatal mucosal enlargement==
- ==Spontaneous bleeding==
- ==Petechiae==</insert>
      <insert timestamp="00:22:48" confidence="8" anchor="- Active monitoring - Splenectomy">

&gt; [!note] Lecturer — Treatment Mechanisms
&gt; Chemotherapy kills cancer cells or slows their growth and may be administered intravenously, by injection under the skin, or as tablets. Stem-cell transplantation introduces healthy stem cells after high-dose chemotherapy.
&gt;
&gt; - Radiotherapy may be used before stem-cell transplantation as conditioning.
&gt; - It may also treat disease involving the central nervous system or testes, or relieve symptoms such as swollen organs or bone pain.
&gt; - Targeted therapies attack specific molecular targets while avoiding healthy cells, including tyrosine-kinase inhibitors and monoclonal antibodies.
</insert>
    </audio_inserts>
  </page>
  <page number="27">
    <text># CHRONIC LYMPHOCYTIC LEUKAEMIA

*   Progression
    *   Can live with slow-growing CLL for long periods (indolent)
    *   Richter’s syndrome (7% patients with CLL): transformation into aggressive NHL (diffuse large B-cell lymphoma) or HL

*   Prognosis
    *   1 in 10 people may never require treatment (active monitoring, “watch and wait”)
        *   immune system fights to keep CLL under control
        *   No survival/symptom benefit, avoid side-effects of treatment
    *   No cure for CLL
        *   But treatments are very effective at controlling symptoms (supportive care)
    *   5-year survival = 88%
    *   Median survival = &gt;10 years</text>
    <formatted_text>#### Progression

- Can live with slow-growing CLL for long periods (indolent)
- Richter's syndrome (7% of patients with CLL): transformation into aggressive NHL (diffuse large B-cell lymphoma) or HL

#### Prognosis

- 1 in 10 people may never require treatment (active monitoring, &quot;watch and wait&quot;)
  - Immune system fights to keep CLL under control
  - No survival/symptom benefit, avoid side-effects of treatment
- No cure for CLL
  - But treatments are very effective at controlling symptoms (supportive care)
- 5-year survival = 88%
- Median survival = &gt;10 years</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:19:02" confidence="9" anchor="- No cure for CLL   - But treatments are very effective at controlling symptoms ">

&gt; [!note] Lecturer — CLL Monitoring
&gt; Some patients undergo several rounds of treatment followed by remission, and some return to watchful monitoring after treatment.
&gt;
&gt; - Active treatment may begin if the disease becomes symptomatic or problematic.
&gt; - Treatment may include chemotherapy or immunotherapy.
</insert>
    </audio_inserts>
  </page>
  <page number="28">
    <text>CHRONIC MYELOID LEUKAEMIA

• Overpopulation of granulocytes (neutrophils, eosinophils, basophils, mast cells)
• Caused be genetic abnormality: Philadelphia chromosome (abnormal chromosome 22)

• Affects adults almost exclusively (usually &gt;60yo)
• 14% of all leukaemias
• Risk factors:
   • Gender – M &gt; F (slightly)
   • Exposure to radiation

![Chromosome 9 Chromosome 22 Philadelphia chromosome BCR gene ABL gene Fusion gene (BCR and ABL combined)](L5.2 Haematology 2 WBC_figures/img_1cfc9462e7735fcc.webp)</text>
    <formatted_text>- Overpopulation of granulocytes (neutrophils, eosinophils, basophils, mast cells)
- Caused by genetic abnormality: Philadelphia chromosome (abnormal chromosome 22)
- Affects adults almost exclusively (usually &gt;60 years old)
- 14% of all leukaemias
- Risk factors:
  - Gender – M &gt; F (slightly)
  - Exposure to radiation</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:19:52" confidence="6" anchor="- Caused by genetic abnormality: Philadelphia chromosome (abnormal chromosome 22">

&gt; [!note] Lecturer — Philadelphia Chromosome
&gt; The Philadelphia chromosome forms when parts of chromosomes 9 and 22 exchange places. This produces the BCR-ABL1 gene, which produces tyrosine kinase, an enzyme involved in controlling cell growth.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="654,534,920,750" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_1cfc9462e7735fcc.webp" caption="Chromosome 9 Chromosome 22 Philadelphia chromosome BCR gene ABL gene Fusion gene (BCR and ABL combined)">
        <description>This labelled diagram illustrates the genetic translocation mechanism creating the Philadelphia chromosome. It depicts normal Chromosome 9 containing the ABL gene and normal Chromosome 22 containing the BCR gene, showing how segments of these chromosomes swap to form a shortened Philadelphia chromosome that carries a fusion gene (BCR and ABL combined).</description>
      </img>
    </images>
  </page>
  <page number="29">
    <text>&lt;h1&gt;CHRONIC MYELOID LEUKAEMIA&lt;/h1&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Features&lt;/strong&gt;
    &lt;ul&gt;
      &lt;li&gt;Symptomatic anaemia (SOB)&lt;/li&gt;
      &lt;li&gt;Fever and sweats in the absence of infection&lt;/li&gt;
      &lt;li&gt;Weight loss&lt;/li&gt;
      &lt;li&gt;Retinal damage&lt;/li&gt;
      &lt;li&gt;Lymphadenopathy – uncommon, suggests transformation to acute leukaemia&lt;/li&gt;
      &lt;li&gt;Progressive splenomegaly (&amp;gt;75%) and associated abdominal discomfort&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
&lt;/ul&gt;</text>
    <formatted_text>#### Features

- Symptomatic anaemia (shortness of breath)
- Fever and sweats in the absence of infection
- Weight loss
- Retinal damage
- Lymphadenopathy – uncommon, suggests transformation to acute leukaemia
- Progressive splenomegaly (&gt;75%) and associated abdominal discomfort</formatted_text>
  </page>
  <page number="30">
    <text>CHRONIC MYELOID LEUKAEMIA

• Progression
  • Can transform to acute phase similar to AML
  • Classified by phase, defined by number of blasts in blood/bone marrow

• Prognosis
  • 5 year survival: 80%

| Chronic phase | Accelerated phase | Blast phase |
| :--- | :--- | :--- |
| High WCC with &lt;5% blast cells | Increase in blast cell counts | Significant increase in blast cell counts |
| asymptomatic | Some symptoms | More symptoms |
| if untreated will eventually progress to accelerated and/or blast phase | if untreated will eventually progress to blast phase | Most aggressive phase. Similar to AML or ALL. |

![](L5.2 Haematology 2 WBC_figures/img_0c6e25ddba8b4de6.webp)</text>
    <formatted_text>#### Progression

- Can transform to acute phase similar to AML
- Classified by phase, defined by number of blasts in blood/bone marrow

#### Prognosis

- 5-year survival: 80%

| Chronic phase | Accelerated phase | Blast phase |
| :--- | :--- | :--- |
| High WCC with &lt;5% blast cells | Increase in blast cell counts | Significant increase in blast cell counts |
| Asymptomatic | Some symptoms | More symptoms |
| If untreated will eventually progress to accelerated and/or blast phase | If untreated will eventually progress to blast phase | Most aggressive phase. Similar to AML or ALL. |</formatted_text>
    <images>
      <img order="0" bbox="313,560,978,832" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_0c6e25ddba8b4de6.webp">
        <description>A three-column table detailing the progression of Chronic Myeloid Leukaemia through its clinical phases. The columns compare the &quot;Chronic phase,&quot; &quot;Accelerated phase,&quot; and &quot;Blast phase&quot; based on blast cell counts, symptom severity, and disease prognosis.</description>
      </img>
    </images>
  </page>
  <page number="31">
    <text>LEUKAEMIA - TREATMENTS

Treatment depends on:
* Type of leukaemia
* Stage of disease
* Severity of symptoms
* Age
* General health
* Patient choice</text>
    <formatted_text>Treatment depends on:

- Type of leukaemia
- Stage of disease
- Severity of symptoms
- Age
- General health
- Patient choice</formatted_text>
  </page>
  <page number="32">
    <text>&lt;h2&gt;LEUKAEMIA - TREATMENTS&lt;/h2&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;Acute leukaemia&lt;/th&gt;
    &lt;th&gt;Chronic leukaemia&lt;/th&gt;
    &lt;th&gt;Palliative Care&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Chemotherapy&lt;br&gt;• Stem cell or bone marrow transplant&lt;br&gt;• Radiotherapy&lt;br&gt;• Steroids&lt;br&gt;• Targeted therapy&lt;br&gt;• Leukapheresis&lt;br&gt;• Immunotherapy (e.g. CAR-T cell therapy)&lt;/td&gt;
    &lt;td&gt;• As for acute&lt;br&gt;• Active monitoring&lt;br&gt;• Splenectomy&lt;/td&gt;
    &lt;td&gt;• Radiotherapy and/or chemotherapy&lt;br&gt;• Analgesics&lt;br&gt;• Blood transfusions&lt;br&gt;• Nutritional supplements / medications for nausea and appetite loss&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>| Acute leukaemia | Chronic leukaemia | Palliative Care |
| :--- | :--- | :--- |
| - Chemotherapy&lt;br&gt;- Stem cell or bone marrow transplant&lt;br&gt;- Radiotherapy&lt;br&gt;- Steroids&lt;br&gt;- Targeted therapy&lt;br&gt;- Leukapheresis&lt;br&gt;- Immunotherapy (e.g. CAR-T cell therapy) | - As for acute&lt;br&gt;- Active monitoring&lt;br&gt;- Splenectomy | - Radiotherapy and/or chemotherapy&lt;br&gt;- Analgesics&lt;br&gt;- Blood transfusions&lt;br&gt;- Nutritional supplements / medications for nausea and appetite loss |</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:23:02" confidence="6" anchor="- Immunotherapy (e.g. CAR-T cell therapy)">

&gt; [!note] Lecturer — Immunotherapy Details
&gt; Leukapheresis uses a machine to remove white cells from the blood, while immunotherapy supports the immune system in recognising and attacking cancer cells.
&gt;
&gt; - CAR T-cell therapy modifies a patient’s own T cells to attack cancer cells.
&gt; - T-cell therapy may cause profound immunosuppression and may require consideration of antibiotic prophylaxis.
</insert>
      <insert timestamp="00:24:20" confidence="9" anchor="- Radiotherapy and/or chemotherapy - Analgesics - Blood transfusions - Nutrition">

&gt; [!note] Lecturer — Advanced Disease Care
&gt; Advanced disease may require shorter or less intensive radiotherapy or chemotherapy.
&gt;
&gt; - Supportive care may include analgesics, blood transfusions, nutritional supplements, and management of nausea and appetite loss.
</insert>
    </audio_inserts>
  </page>
  <page number="33">
    <text># LYMPHOMAS</text>
  </page>
  <page number="34">
    <text>
| | Leukaemia | Lymphoma |
| :--- | :--- | :--- |
| Origins/affects | Originates in bone marrow, circulates through bloodstream | Lymphocytes in the lymph nodes, spleen and other lymphatic tissue&lt;br&gt;&lt;br&gt;Forms solid masses |
| Signs and symptoms | Bone pain, easy bruising or bleeding, petechiae, pallor, fatigue, fevers, frequent infections | Lymphadenopathy, itchy skin (without clear rash), fevers, coughing/SOB, weight loss, night sweats |

![LEUKAEMIA VS LYMPHOMA](L5.2 Haematology 2 WBC_figures/img_8ddcad8478eccfe3.webp)</text>
    <formatted_text>| | Leukaemia | Lymphoma |
| :--- | :--- | :--- |
| Origins/affects | Originates in bone marrow, circulates through bloodstream | Lymphocytes in the lymph nodes, spleen and other lymphatic tissue; forms solid masses |
| Signs and symptoms | Bone pain, easy bruising or bleeding, petechiae, pallor, fatigue, fevers, frequent infections | Lymphadenopathy, itchy skin (without clear rash), fevers, coughing/SOB, weight loss, night sweats |</formatted_text>
    <images>
      <img order="0" bbox="51,317,923,638" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_8ddcad8478eccfe3.webp" caption="LEUKAEMIA VS LYMPHOMA">
        <description>A comparison table contrasting Leukaemia and Lymphoma across two categories: Origins/affects and Signs and symptoms. The table details that Leukaemia originates in the bone marrow and circulates through the bloodstream, causing symptoms like bone pain and bruising, whereas Lymphoma affects lymphocytes in nodes and tissue, forming solid masses with symptoms including lymphadenopathy and night sweats.</description>
      </img>
    </images>
  </page>
  <page number="35">
    <text># LYMPHOMA - DEFINITIONS

• Lymphoma = B- and T-cell (lymphotcyle) malignancies of the lymphoid system
• Hodgkin Lymphoma = haematological malignancy arising from mature B-cells, with presence of Reed-Sternberg cells and Hodgkin cells
• Non-Hodgkin Lymphoma = haematological malignancy arising from mature B or T-cells (lymphocytes), without presence of Reed-Sternberg cells
    • More than 60 subtypes of NHL, including:
        • Follicular lymphoma
        • Diffuse Large B-cell lymphoma (DLBCL)
        • Burkitt’s lymphoma
• Divided into B-cell and T-cell NHLs
    • T-cell lymphomas generally harder to cure

Normal lymphocyte
Reed-Sternberg Cell

![Normal lymphocyte Reed-Sternberg Cell](L5.2 Haematology 2 WBC_figures/img_428e6d409bbcda3e.webp)</text>
    <formatted_text>- Lymphoma = B- and T-cell (lymphocyte) malignancies of the lymphoid system
- Hodgkin Lymphoma = haematological malignancy arising from mature B-cells, with presence of Reed-Sternberg cells and Hodgkin cells
- Non-Hodgkin Lymphoma = haematological malignancy arising from mature B or T-cells (lymphocytes), without presence of Reed-Sternberg cells
  - More than 60 subtypes of NHL, including:
    - Follicular lymphoma
    - Diffuse Large B-cell lymphoma (DLBCL)
    - Burkitt's lymphoma
- Divided into B-cell and T-cell NHLs
  - T-cell lymphomas generally harder to cure

*Normal lymphocyte; Reed-Sternberg cell*</formatted_text>
    <images>
      <img order="0" bbox="682,588,806,792" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_428e6d409bbcda3e.webp" caption="Normal lymphocyte Reed-Sternberg Cell">
        <description>A micrograph of a stained blood smear showing a large Reed-Sternberg cell in the center, characterized by its abundant cytoplasm and binucleated appearance with prominent nucleoli (often described as &quot;owl's eyes&quot;). Surrounding this central cell are numerous smaller normal lymphocytes with dark, round nuclei. The image illustrates the morphological contrast between the malignant cells found in Hodgkin Lymphoma and normal lymphoid cells.</description>
      </img>
    </images>
  </page>
  <page number="36">
    <text>LYMPHOMA - AETIOLOGY

• Unknown exact cause
• Risk factors:

| Hodgkin Lymphoma | Non-Hodgkin Lymphoma |
| :--- | :--- |
| • Sex: M&gt;F | • Sex: M&gt;F |
| • Age: 20-24yo, 75-79yo | • European origin |
| • Low immunity (e.g. autoimmune condition, HIV 11x ↑ risk, AIDS 3x ↑ risk) | • Age: any, but 35% are &gt;75yo |
| • Ebstein-Barr virus (assoc with 40% HL cases) | • Low immunity (e.g. autoimmune condition, immunosuppressants for transplant) |
| • Previous NHL (?tx for NHL) | • Infections |
| • Family history HL, NHL or CLL | • H. pylori (MALT lymphoma in stomach) |
| • Overweight | • HIV (DLBCL lymphohoma) $\rightarrow$ ↓ incidence since HAART |
| • Smoking | • T-cell lymphoma virus 1 (HTLV1) |
| | • EBV |
| | • Hepatitis C |
| | • Coeliac disease (EATL lymphoma) |
| | • Family history NHL |
| | • Previous cancer treatment |
| | • Breast implant associated anaplastic large cell lymphoma |

![](L5.2 Haematology 2 WBC_figures/img_4bd9c86912057928.webp)</text>
    <formatted_text>- Unknown exact cause

#### Risk Factors

| Hodgkin Lymphoma | Non-Hodgkin Lymphoma |
| :--- | :--- |
| Sex: M&gt;F | Sex: M&gt;F |
| Age: 20-24yo, 75-79yo | European origin |
| Low immunity (e.g. autoimmune condition, HIV 11x ↑ risk, AIDS 3x ↑ risk) | Age: any, but 35% are &gt;75yo |
| Epstein-Barr virus (assoc with 40% HL cases) | Low immunity (e.g. autoimmune condition, immunosuppressants for transplant) |
| Previous NHL (?tx for NHL) | Infections |
| Family history HL, NHL or CLL | H. pylori (MALT lymphoma in stomach) |
| Overweight | HIV (DLBCL lymphoma) → ↓ incidence since HAART |
| Smoking | T-cell lymphoma virus 1 (HTLV1) |
| | EBV |
| | Hepatitis C |
| | Coeliac disease (EATL lymphoma) |
| | Family history NHL |
| | Previous cancer treatment |
| | Breast implant associated anaplastic large cell lymphoma |</formatted_text>
    <images>
      <img order="0" bbox="67,292,920,795" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_4bd9c86912057928.webp">
        <description>A two-column comparison table listing risk factors for Hodgkin Lymphoma and Non-Hodgkin Lymphoma. The left column details factors such as age, sex, and EBV status, while the right column lists additional risks including specific infections (H. pylori, HIV, HTLV1) and autoimmune conditions.</description>
      </img>
    </images>
  </page>
  <page number="37">
    <text>LYMPHOMA
GENERAL MANIFESTATIONS

| Hodgkin Lymphoma | Non-Hodgkin Lymphoma |
| :--- | :--- |
| Lymphadenopathy&lt;br&gt;- Contiguous spread | Lymphadenopathy&lt;br&gt;- Non-contiguous spread (often disseminated disease)&lt;br&gt;- Predilection for GIT and CNS |

* Fatigue
* B-symptoms: unexplained fevers, night sweats, weight loss
* Itchy skin
* Pressure on other organs/ducts/nerves

![](L5.2 Haematology 2 WBC_figures/img_75f2445e9ecaeeed.webp)</text>
    <formatted_text>| Hodgkin Lymphoma | Non-Hodgkin Lymphoma |
| :--- | :--- |
| Lymphadenopathy — contiguous spread | Lymphadenopathy — non-contiguous spread (often disseminated disease); predilection for GIT and CNS |

- Fatigue
- B-symptoms: unexplained fevers, night sweats, weight loss
- Itchy skin
- Pressure on other organs/ducts/nerves</formatted_text>
    <images>
      <img order="0" bbox="52,363,924,527" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_75f2445e9ecaeeed.webp">
        <description>A two-column table comparing the general manifestations of Hodgkin Lymphoma and Non-Hodgkin Lymphoma. It highlights differences in lymphadenopathy spread, noting contiguous spread for Hodgkin's versus non-contiguous spread and specific organ predilections (GIT and CNS) for Non-Hodgkin's.</description>
      </img>
    </images>
  </page>
  <page number="38">
    <text>LYMPHOMA
H&amp;N MANIFESTATIONS

• Hodgkin Lymphoma
  • Rarely affects mouth
  • If does, clinically indistinguishable from NHL

• Non-Hodgkin Lymphoma
  • Enlarged cervical lymph nodes (discrete, rubbery, painless)
    • initial complaint in 50% of cases
  • Swellings and ulcers
    • especially palate and fauces (often associated with AIDS)
    • Also gingiva, FOM
  • Isolated tooth mobility or lip paraesthesia
  • Rarely: involvement of Waldeyer’s ring (more commonly in HIV-infected, NHL&gt;HL)

![](L5.2 Haematology 2 WBC_figures/img_a64b85811fa2f7c4.webp)</text>
    <formatted_text>#### Hodgkin Lymphoma

- Rarely affects mouth
- If does, clinically indistinguishable from NHL

#### Non-Hodgkin Lymphoma

- Enlarged cervical lymph nodes (discrete, rubbery, painless) — initial complaint in 50% of cases
- Swellings and ulcers
  - especially palate and fauces (often associated with AIDS)
  - also gingiva, FOM
- Isolated tooth mobility or lip paraesthesia
- Rarely: involvement of Waldeyer's ring (more commonly in HIV-infected, NHL&gt;HL)</formatted_text>
    <images>
      <img order="0" bbox="655,263,896,672" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_a64b85811fa2f7c4.webp">
        <description>A clinical photograph showing a lateral view of a patient's neck and upper chest. The subject is pulling down the collar of a black shirt to expose the skin, revealing a visible swelling or mass in the lower cervical/supraclavicular region.</description>
      </img>
    </images>
  </page>
  <page number="39">
    <text>LYMPHOMA GENERAL MANAGEMENT

Staging
Ann Arbor staging
• How many areas affected
• Above, below or on both sides of diaphragm
• Whether has spread to bone marrow or other organs

Ann Arbor staging (1):

Treatment
• Watch and wait (active monitoring)
  • Low-grade slow-growing lymphomas
• Radiotherapy
• Chemotherapy
• Immunotherapy / targeted therapies
• Stem cell transplant
• Palliative Care

![Stage I: involvement of single lymph node region or single extralymphatic site (Ie)](L5.2 Haematology 2 WBC_figures/img_92dd23881b074186.webp)
![Stage II: involvement of two or more lymph node regions on same side of diaphragm; may include localized extralymphatic](L5.2 Haematology 2 WBC_figures/img_b4ed7db3afbf8b3f.webp)
![Stage III: involvement of lymph node regions on both sides of the diaphragm; may include spleen (IIIe) or localized](L5.2 Haematology 2 WBC_figures/img_a86c76d06e51e4f9.webp)
![Stage IV: diffuse extralymphatic disease (e.g. in liver, bone marrow, lung, skin)](L5.2 Haematology 2 WBC_figures/img_213b3ee0c6f3aabd.webp)</text>
    <formatted_text>#### Staging

Ann Arbor staging:
- How many areas affected
- Above, below or on both sides of diaphragm
- Whether has spread to bone marrow or other organs

#### Treatment

- Watch and wait (active monitoring) — low-grade slow-growing lymphomas
- Radiotherapy
- Chemotherapy
- Immunotherapy / targeted therapies
- Stem cell transplant
- Palliative care</formatted_text>
    <images>
      <img order="0" bbox="145,572,211,723" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_92dd23881b074186.webp" caption="Stage I: involvement of single lymph node region or single extralymphatic site (Ie)">
        <description>A schematic anterior view of the human torso, neck, and pelvis illustrating lymph node regions. A cluster of red circles on the left side of the neck indicates localized involvement in a single region, corresponding to Stage I.</description>
      </img>
      <img order="1" bbox="142,571,447,724" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_b4ed7db3afbf8b3f.webp" caption="Stage II: involvement of two or more lymph node regions on same side of diaphragm; may include localized extralymphatic">
        <description>A set of four schematic diagrams illustrating the progression of lymphoma staging (I-IV) on human torsos. Red dots mark affected lymph node regions, while stippled areas represent extralymphatic involvement in organs like the liver and spleen.</description>
      </img>
      <img order="2" bbox="222,573,290,723" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L5.2 Haematology 2 WBC_figures/img_a86c76d06e51e4f9.webp" caption="Stage III: involvement of lymph node regions on both sides of the diaphragm; may include spleen (IIIe) or localized">
        <description>A schematic anterior view of the human torso and pelvis illustrating lymph node involvement. Red clusters of dots mark affected regions in the neck (cervical) and chest/mediastinum, while the abdomen and pelvic nodes remain unmarked.</description>
      </img>
      <img order="3" bbox="301,574,368,723" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_213b3ee0c6f3aabd.webp" caption="Stage IV: diffuse extralymphatic disease (e.g. in liver, bone marrow, lung, skin)">
        <description>A schematic anterior view of a human torso showing the skeletal structure (ribs, spine, pelvis) with red dots indicating widespread involvement in multiple extralymphatic sites such as the neck, axilla, and pelvic region. This visualizes Stage IV disease characterized by diffuse spread to organs or tissues outside the lymph nodes.</description>
      </img>
    </images>
  </page>
  <page number="40">
    <text>LYMPHOMA PROGNOSIS

Hodgkin Lymphoma
• HL:
  • 85–95% 5-year survival (stage 1-4)
  • 80% 10-year survival
• NHL
  • Prognosis variable based on type
  • Generally 65% 5-year survival, 55% 10-year survival

| | Low grade NHL | High grade NHL |
| :--- | :--- | :--- |
| **Growth** | Indolent | Aggressive |
| **Age** | &gt;50 years | Children / young adults |
| **Cure rate** | Rare&lt;br&gt;Relapse common | Higher |
| **Common types** | Follicular | DLBCL&lt;br&gt;Burkitt’s&lt;br&gt;Peripheral T cell |

![](L5.2 Haematology 2 WBC_figures/img_f7522a56b4ed54e5.webp)</text>
    <formatted_text>#### Hodgkin Lymphoma

- 85–95% 5-year survival (stage 1-4)
- 80% 10-year survival

#### Non-Hodgkin Lymphoma

- Prognosis variable based on type
- Generally 65% 5-year survival, 55% 10-year survival

| | Low grade NHL | High grade NHL |
| :--- | :--- | :--- |
| Growth | Indolent | Aggressive |
| Age | &gt;50 years | Children / young adults |
| Cure rate | Rare; relapse common | Higher |
| Common types | Follicular | DLBCL, Burkitt's, Peripheral T cell |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:31:13" confidence="10" anchor="| Cure rate | Rare; relapse common | Higher | | Common types | Follicular | DLBC">

&gt; [!note] Lecturer — NHL Prognosis
&gt; Low-grade lymphoma may be difficult to eradicate completely but can remain controlled for several years.
&gt;
&gt; - High-grade lymphoma requires more intensive treatment but often responds better.
&gt; - Many patients with high-grade disease are cured.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="482,370,930,681" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_f7522a56b4ed54e5.webp">
        <description>A comparison table contrasting Low grade NHL and High grade NHL across four clinical parameters: Growth, Age, Cure rate, and Common types. It illustrates that low grade disease is indolent, affects older adults (&gt;50 years), has rare cures with common relapse (e.g., Follicular), while high grade disease is aggressive, affects children/young adults, has higher cure rates, and includes types like DLBCL, Burkitt's, and Peripheral T cell.</description>
      </img>
    </images>
  </page>
  <page number="41">
    <text>**MYELODYSPLASTIC SYNDROMES (MDS)**

(MYELODYSPLASIA)</text>
    <formatted_text>Myelodysplastic Syndromes (MDS)

*(Myelodysplasia)*</formatted_text>
  </page>
  <page number="42">
    <text>MYELODYSPLASTIC SYNDROMES

• Definition: group of clonal haematopoietic stem cell disorders caused by a mutation that results in abnormal proliferation of myeloid progenitor cells, usually in the presence of a hypercellular bone marrow and multilineage dysplasia.

Aetiology
• Mutation in ≥1 genes that control blood cell development
• Affected stem cell divides  “clones” of defective stem cell produced (preservation of mutation)
• Bone marrow gradually overtaken by abnormally functioning immature blood cells
• Results in lower production of mature myeloid cells (ineffective haematopoiesis)
• Bone marrow gradually overtaken by abnormally functioning immature blood cells (progressive cytopenia)

Usually all 3 cell lines (erythroid, megakaryocyte, granulocyte) involved, with increased risk of AML development.

Haemopoietic stem cell
Common myeloid progenitor
Common lymphoid progenitor
Megakaryocyte erythroid progenitor
Granulocyte macrophage progenitor
Megakaryocyte
Erythroblast
B cell progenitor
T cell progenitor
Platelet
Erythrocyte
Neutrophil
Eosinophil
Basophil
Dendritic cell
B cell
T cell
NK cell

![](L5.2 Haematology 2 WBC_figures/img_3fa1be43a602fd09.webp)</text>
    <formatted_text>#### Definition

A group of clonal haematopoietic stem cell disorders caused by a mutation that results in abnormal proliferation of myeloid progenitor cells, usually in the presence of a hypercellular bone marrow and multilineage dysplasia.

#### Aetiology

- Mutation in ≥1 genes that control blood cell development
- Affected stem cell divides → &quot;clones&quot; of defective stem cell produced (preservation of mutation)
- Bone marrow gradually overtaken by abnormally functioning immature blood cells
- Results in lower production of mature myeloid cells (ineffective haematopoiesis), with progressive cytopenia

Usually all 3 cell lines (erythroid, megakaryocyte, granulocyte) involved, with increased risk of AML development.

#### Haematopoietic Cell Lineage

- Haemopoietic stem cell
  - Common myeloid progenitor
    - Megakaryocyte erythroid progenitor
      - Megakaryocyte → Platelet
      - Erythroblast → Erythrocyte
    - Granulocyte macrophage progenitor
      - Neutrophil, Eosinophil, Basophil
      - Dendritic cell
  - Common lymphoid progenitor
    - B cell progenitor → B cell
    - T cell progenitor → T cell
    - NK cell</formatted_text>
    <images>
      <img order="0" bbox="518,460,942,781" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_3fa1be43a602fd09.webp">
        <description>A hierarchical flowchart illustrating haematopoiesis, showing the differentiation pathway from a central Haemopoietic stem cell into various progenitor cells and mature blood cell types. The diagram branches into myeloid and lymphoid lineages, with red circles highlighting specific stages including the Granulocyte macrophage progenitor, Megakaryocyte, and Erythroblast.</description>
      </img>
    </images>
  </page>
  <page number="43">
    <text>MYELODYSPLASTIC SYNDROMES
MANIFESTATIONS

**General Findings**

*   Related to increasing bone marrow failure
    *   &lt;u&gt;Red blood cells (macrocytic anaemia)&lt;/u&gt;: weakness, tiredness/fatigue, SOB with minimal exercise, pallor.
    *   &lt;u&gt;White blood cells (neutropenia)&lt;/u&gt;: frequent infections (especially chest infections), fevers.
    *   &lt;u&gt;Platelets (thrombocytopenia)&lt;/u&gt;: bruising, easy bleeding (nosebleeds), purpura/petechiae (lower limbs initially)
*   Enlargement of spleen or liver

**Oral Findings**

*   Related to increasing bone marrow failure
    *   White blood cells: sore mouth (mouth ulcers), oral infections (herpes, fungal, bacterial), exacerbation of chronic periodontitis and/or dental infection
    *   Platelets: spontaneous gingival bleeding, petechiae
*   Gingival infiltration and oral ulceration may develop in CMML subtype. May be first sign of acceleration of a stable disease process.
*   Paraesthesia, burning mouth, xerostomia reported</text>
    <formatted_text>#### General Findings

Related to increasing bone marrow failure:

- Red blood cells (macrocytic anaemia): weakness, tiredness/fatigue, SOB with minimal exercise, pallor
- White blood cells (neutropenia): frequent infections (especially chest infections), fevers
- Platelets (thrombocytopenia): bruising, easy bleeding (nosebleeds), purpura/petechiae (lower limbs initially)
- Enlargement of spleen or liver

#### Oral Findings

Related to increasing bone marrow failure:

- White blood cells: sore mouth (mouth ulcers), oral infections (herpes, fungal, bacterial), exacerbation of chronic periodontitis and/or dental infection
- Platelets: spontaneous gingival bleeding, petechiae

- Gingival infiltration and oral ulceration may develop in CMML subtype. May be first sign of acceleration of a stable disease process.
- Paraesthesia, burning mouth, xerostomia reported</formatted_text>
  </page>
  <page number="44">
    <text>MYELODYSPLASTIC SYNDROMES
GENERAL MANAGEMENT

Supportive Treatment
• Growth factor injections (erythropoietin, G-CSF)
• Blood transfusions (RBCs, platelets)
• Iron chelating agents
• Antibiotics (if low WBCs)
• Supplements: folic acid, Vit B6
• Systemic corticosteroids

Active Treatment
• Targeted therapy (e.g. lenalidomide)
• Chemotherapy
• Stem cell transplant
• Clinical trials</text>
    <formatted_text>#### Supportive Treatment

- Growth factor injections (erythropoietin, G-CSF)
- Blood transfusions (RBCs, platelets)
- Iron chelating agents
- Antibiotics (if low WBCs)
- Supplements: folic acid, Vit B6
- Systemic corticosteroids

#### Active Treatment

- Targeted therapy (e.g. lenalidomide)
- Chemotherapy
- Stem cell transplant
- Clinical trials</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:32:30" confidence="6" anchor="Blood transfusions (RBCs, platelets) - Iron chelating agents - Antibiotics (if l">
- ==Iron-chelating agents reduce excess iron after repeated transfusions.==</insert>
    </audio_inserts>
  </page>
  <page number="45">
    <text>MYELOPROLIFERATIVE
NEOPLASMS

**MYELOPROLIFERATIVE DISORDERS**</text>
    <formatted_text>*Myeloproliferative disorders*</formatted_text>
  </page>
  <page number="46">
    <text># MYELOPROLIFERATIVE NEOPLASMS

*   Definition: A heterogenous group of clonal haematopoietic stem cell disorders caused by a mutation whereby abnormal myeloid *progenitor* cells (erythroid, myeloid, megakaryocyte) produce excess numbers of &lt;u&gt;one or more&lt;/u&gt; &lt;u&gt;cell types.&lt;/u&gt;

*   Classification: FAB / WHO
    *   Usually described according to most affected blood cell type. Four commonest subtypes:

&gt; Polycythaemia vera (PV): excessive &lt;u&gt;RBCs&lt;/u&gt;

&gt; Essential thrombocythaemia (ET): excessive &lt;u&gt;platelets&lt;/u&gt;

&gt; Chronic myelogenous leukaemia (CML): excessive &lt;u&gt;WBCs&lt;/u&gt;

&gt; Myelofibrosis (MF): replacement of the stem cells in the bone marrow by scar and fibrous tissue (&lt;u&gt;fibroblasts&lt;/u&gt;), resulting in too few blood cells and often an enlarged spleen.</text>
    <formatted_text>- **Definition:** A heterogenous group of clonal haematopoietic stem cell disorders caused by a mutation whereby abnormal myeloid *progenitor* cells (erythroid, myeloid, megakaryocyte) produce excess numbers of one or more cell types.
- **Classification:** FAB / WHO
    - Usually described according to most affected blood cell type. Four commonest subtypes:

&gt; - Polycythaemia vera (PV): excessive RBCs
&gt; - Essential thrombocythaemia (ET): excessive platelets
&gt; - Chronic myelogenous leukaemia (CML): excessive WBCs
&gt; - Myelofibrosis (MF): replacement of the stem cells in the bone marrow by scar and fibrous tissue (fibroblasts), resulting in too few blood cells and often an enlarged spleen.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:33:24" confidence="11" anchor="- **Definition:** A heterogenous group of clonal haematopoietic stem cell disord">

&gt; [!note] Lecturer — Blood Cell Production
&gt; The marrow rapidly produces functional mature blood cells, causing blood-cell counts to become high.
&gt;
&gt; - ==Blood may become thick== as a result.
</insert>
    </audio_inserts>
  </page>
  <page number="47">
    <text>MYELOPROLIFERATIVE NEOPLASMS

• General Features
• Symptoms related to deficient &lt;span style=&quot;color: orange;&quot;&gt;blood cells&lt;/span&gt; (RBC, WBC, platelets)
• &lt;span style=&quot;color: orange;&quot;&gt;Thrombosis, blood hyperviscosity&lt;/span&gt; (MF, PV, ET): brain (stroke/TIA), eyes (vision), heart (MI), legs (DVT), lungs (PE)
• &lt;span style=&quot;color: orange;&quot;&gt;Splenomegaly&lt;/span&gt; and &lt;span style=&quot;color: orange;&quot;&gt;hepatomegaly&lt;/span&gt; (MF, PV, ET): secondary to extramedullary haematopoiesis → abdominal pain, appetite loss, pain on respiration
• &lt;span style=&quot;color: orange;&quot;&gt;Gout&lt;/span&gt; (MF, PV, ET): increased production and breakdown of blood cells → build up of uric acid
• &lt;span style=&quot;color: orange;&quot;&gt;Aquagenic pruritis&lt;/span&gt; (PV): itchy skin following a contact with water
• &lt;span style=&quot;color: orange;&quot;&gt;Bone pain&lt;/span&gt; (MF)
• Night sweats, pyrexia, weight loss, pruritic, dizziness, weakness (MF)
• &lt;span style=&quot;color: orange;&quot;&gt;Vasomotor symptoms&lt;/span&gt;: headaches, dizziness, tingling, erythromelalgia, visual disturbances (ET)</text>
    <formatted_text>- Symptoms related to deficient blood cells (RBC, WBC, platelets)
- Thrombosis, blood hyperviscosity (MF, PV, ET): brain (stroke/TIA), eyes (vision), heart (MI), legs (DVT), lungs (PE)
- Splenomegaly and hepatomegaly (MF, PV, ET): secondary to extramedullary haematopoiesis → abdominal pain, appetite loss, pain on respiration
- Gout (MF, PV, ET): increased production and breakdown of blood cells → build up of uric acid
- Aquagenic pruritis (PV): itchy skin following a contact with water
- Bone pain (MF)
- Night sweats, pyrexia, weight loss, pruritic, dizziness, weakness (MF)
- Vasomotor symptoms: headaches, dizziness, tingling, erythromelalgia, visual disturbances (ET)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:35:41" confidence="6" anchor="- Vasomotor symptoms: headaches, dizziness, tingling, erythromelalgia, visual di">
- ==Aquagenic pruritus may be unbearable== after contact with water
- Erythromelalgia may cause ==burning pain in the hands and feet with redness and warmth==</insert>
    </audio_inserts>
  </page>
  <page number="48">
    <text>MYELOPROLIFERATIVE NEOPLASMS

• General Management
  • Depends on specific subtype

| Supportive Treatment (Symptom specific) | Active treatment |
| :--- | :--- |
| • Venesection: removal of measured amount of blood to lower RBC volume and thickness (PV) | • Watch and wait |
| • Blood transfusions (MF) | • Cytoreductive therapy (e.g. hydroxycarbamide, interferon): slow bone marrow’s production of blood cells |
| • Supplements: folic acid (MF) | • Chemotherapy |
| • Allopurinol: gout (MV, PV, ET) | • Targeted therapy (JAK inhibitors): symptoms, treat splenomegaly |
| • Splenomegaly: hydroxycarbamide, interferon, radiation, splenectomy (MF) | • Stem cell transplant |
| • Corticosteroids (MF) | |
| • Aspirin: prevent abnormal blood clotting and reduce cardiovascular risks (MF, PV, ET) | |
| • Antihistamines: itching (PV) | |

![](L5.2 Haematology 2 WBC_figures/img_4fa287503589158d.webp)</text>
    <formatted_text>General management depends on the specific subtype.

#### Supportive Treatment (Symptom Specific)

- Venesection: removal of measured amount of blood to lower RBC volume and thickness (PV)
- Blood transfusions (MF)
- Supplements: folic acid (MF)
- Allopurinol: gout (MF, PV, ET)
- Splenomegaly: hydroxycarbamide, interferon, radiation, splenectomy (MF)
- Corticosteroids (MF)
- Aspirin: prevent abnormal blood clotting and reduce cardiovascular risks (MF, PV, ET)
- Antihistamines: itching (PV)

#### Active Treatment

- Watch and wait
- Cytoreductive therapy (e.g. hydroxycarbamide, interferon): slow bone marrow's production of blood cells
- Chemotherapy
- Targeted therapy (JAK inhibitors): symptoms, treat splenomegaly
- Stem cell transplant</formatted_text>
    <images>
      <img order="0" bbox="99,376,929,764" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_4fa287503589158d.webp">
        <description>A two-column comparison table outlining the management of myeloproliferative neoplasms. The left column lists supportive, symptom-specific treatments (such as venesection, transfusions, and aspirin), while the right column details active treatment options (including cytoreductive therapy, chemotherapy, and stem cell transplant).</description>
      </img>
    </images>
  </page>
  <page number="49">
    <text>MYELOPROLIFERATIVE NEOPLASMS

• Dental Implications
  • Oral manifestations and risk management as per blood cells affected
  • Related to treatments provided
  • Paradoxical clotting and bleeding tendency
    • Haemostasis
    • Cardiovascular risks (e.g. MI, stroke)
  • Aquagenic pruritic (PV): ability to operate, oral hygiene at home
  • Erythromelalgia (burning pain of hands): oral hygiene ability
  • Splenic changes: infection risk</text>
    <formatted_text>- Oral manifestations and risk management as per blood cells affected
- Related to treatments provided
- Paradoxical clotting and bleeding tendency
    - Haemostasis
    - Cardiovascular risks (e.g. MI, stroke)
- Aquagenic pruritic (PV): ability to operate, oral hygiene at home
- Erythromelalgia (burning pain of hands): oral hygiene ability
- Splenic changes: infection risk</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:37:41" confidence="3" anchor="- Splenic changes: infection risk">
- ==Anticoagulant or aspirin therapy may affect dental treatment==
- Dental treatment may need to be performed ==slowly and carefully when contact with water is difficult== because of aquagenic pruritus</insert>
    </audio_inserts>
  </page>
  <page number="50">
    <text/>
  </page>
  <page number="51">
    <text>Antigen
Antigen receptor
B cell
Cytokines
Helper T cell

PLASMA CELL
TUMOURS

1. *Multiple myeloma
2. Solitary myeloma
3. Waldenstrom’s macroglobulinaemia
4. Heavy chain disease
5. Monoclonal gammopathy of
undetermined significance (MGUS)

Memory
cell
Plasma
cell
Antibodies

![](L5.2 Haematology 2 WBC_figures/img_aadb7e08a72298fc.webp)</text>
    <formatted_text>*Plasma cell tumours comprise:*

1. Multiple myeloma
2. Solitary myeloma
3. Waldenstrom's macroglobulinaemia
4. Heavy chain disease
5. Monoclonal gammopathy of undetermined significance (MGUS)

*Diagram labels: B cell → antigen receptor (antigen); cytokines from helper T cell; differentiation to memory cell and plasma cell → antibodies.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:20:01" confidence="2" anchor="5. Monoclonal gammopathy of undetermined significance (MGUS)">
- ==Plasma-cell tumours are also called paraproteinaemias.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="27,191,430,809" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_aadb7e08a72298fc.webp">
        <description>A labelled schematic diagram illustrating the differentiation of a B cell into memory and plasma cells upon antigen stimulation. The flowchart shows a Helper T cell releasing cytokines to activate a B cell with an antigen receptor, which then proliferates and differentiates into either a Memory cell or an antibody-secreting Plasma cell.</description>
      </img>
    </images>
  </page>
  <page number="52">
    <text># MULTIPLE MYELOMA

*   Definition: Disseminated plasma cell neoplasm, predominantly causing bone lesions. Malignant plasma cells produce defective immunoglobulins and release osteoclast-activation factors, causing bone resorption and pain.

*   Aetiology: Exact reason unknown.
    *   Occasionally related to ionising radiation and petroleum products exposure.
    *   Associated with MGUS (1/100 develop MM), ethnicity (twice as common in black population than white/Asians)
    *   Mostly middle-age and elderly
    *   Slight predilection for males</text>
    <formatted_text>- **Definition:** Disseminated plasma cell neoplasm, predominantly causing bone lesions. Malignant plasma cells produce defective immunoglobulins and release osteoclast-activation factors, causing bone resorption and pain.

- **Aetiology:** Exact reason unknown.
  - Occasionally related to ionising radiation and petroleum products exposure.
  - Associated with MGUS (1/100 develop MM), ethnicity (twice as common in black population than white/Asians)
  - Mostly middle-age and elderly
  - Slight predilection for males</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:38:55" confidence="7" anchor="Malignant plasma cells produce defective immunoglobulins and release osteoclast-">
- ==Multiple myeloma is the most common plasma-cell malignancy discussed.==</insert>
    </audio_inserts>
  </page>
  <page number="53">
    <text>MULTIPLE MYELOMA
CLINICAL FEATURES (OF RELEVANCE TO DENTISTRY)

• Neoplastic proliferation of plasma cells in bone marrow
→ release of cytokines →
• Osteolysis and bone destruction
• Mandibular lesions: 5–14% of patients
• Promote dental mobility, pain, paraesthesia, soft tissue swelling, pathological jaw fractures
• Suppression of haemopoiesis and bone marrow replacement →
• RBC: anaemia
• WBC: increased risk of infections (leukopenia, abnormal antibody production)
• Platelets: bleeding tendency (thrombocytopenia)

• Defective immunoglobulin (hyperglobulinemia with paradoxical hypogammaglobulinemia) →
• Plasma hyperviscosity with clotting or bleeding tendency
• Renal failure
• Increased liability to infections
• Neurological sequelae

Raghavan S, Nagaraj P, Ramaswamy B, Nayak D. Multiple Myeloma of the jaw: A Case Report. J Indian Acad Oral Med Radiol, 2014, 26(4):454-457.

![Shows multiple punchout radiolucencies](L5.2 Haematology 2 WBC_figures/img_c4b29a91cbf182ad.webp)</text>
    <formatted_text>- Neoplastic proliferation of plasma cells in bone marrow → release of cytokines →
  - Osteolysis and bone destruction
  - Mandibular lesions: 5–14% of patients
  - Promote dental mobility, pain, paraesthesia, soft tissue swelling, pathological jaw fractures
- Suppression of haemopoiesis and bone marrow replacement →
  - RBC: anaemia
  - WBC: increased risk of infections (leukopenia, abnormal antibody production)
  - Platelets: bleeding tendency (thrombocytopenia)
- Defective immunoglobulin (hyperglobulinemia with paradoxical hypogammaglobulinemia) →
  - Plasma hyperviscosity with clotting or bleeding tendency
  - Renal failure
  - Increased liability to infections
  - Neurological sequelae

*Raghavan S, Nagaraj P, Ramaswamy B, Nayak D. Multiple Myeloma of the jaw: A Case Report. J Indian Acad Oral Med Radiol, 2014, 26(4):454-457.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:41:28" confidence="3" anchor="Mandibular lesions: 5–14% of patients">
    - ==Multiple punched-out radiolucencies.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="476,206,938,782" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L5.2 Haematology 2 WBC_figures/img_c4b29a91cbf182ad.webp" caption="Shows multiple punchout radiolucencies">
        <description>A radiograph of a human skull in an anterior-posterior view, showing the cranium, orbits, nasal cavity, and mandible. The image illustrates multiple small, dark circular spots scattered across the frontal bone (forehead area), which are characteristic punched-out radiolucencies.</description>
      </img>
    </images>
  </page>
  <page number="54">
    <text>MULTIPLE MYELOMA
CLINICAL FEATURES (OF RELEVANCE TO DENTISTRY)

• Associated with extramedullary plasmacytoma

Merino F, Portillo Hernandez I, Sanchez Aniceto G, Ballestin C. Extramedullary plasmacytoma in the maxillofacial region: A review of the literature and case report. Oral Maxillofac Surg Cases. 2018; 4(4): 141-145.

![](L5.2 Haematology 2 WBC_figures/img_17c20845bad5457b.webp)
![](L5.2 Haematology 2 WBC_figures/img_2a65017d254e23f9.webp)
![](L5.2 Haematology 2 WBC_figures/img_c83c8fd61210cb7c.webp)</text>
    <formatted_text>- Associated with extramedullary plasmacytoma

*Merino F, Portillo Hernandez I, Sanchez Aniceto G, Ballestin C. Extramedullary plasmacytoma in the maxillofacial region: A review of the literature and case report. Oral Maxillofac Surg Cases. 2018; 4(4): 141-145.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:42:31" confidence="9" anchor="Associated with extramedullary plasmacytoma  *Merino F, Portillo Hernandez I, Sa">

&gt; [!note] Lecturer — Extramedullary Plasmacytomas
&gt; Extramedullary plasmacytomas are uncommon solitary tumours composed of neoplastic plasma cells occurring outside bone.
&gt;
&gt; - They primarily arise in the head and neck, accounting for 80–90% of extramedullary plasmacytomas in that region.
&gt; - They represent approximately 1% of head and neck tumours and commonly involve the nasal cavity, nasopharynx, and maxillary sinus.
&gt; - Oral-cavity involvement is rare, and they occur in approximately 20% of multiple-myeloma recurrences.
&gt; - Extramedullary plasmacytomas may progress to multiple myeloma.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="57,448,280,693" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_17c20845bad5457b.webp">
        <description>Clinical photograph showing the lower face of an adult patient with significant bilateral swelling of the cheeks and jaw area.</description>
      </img>
      <img order="1" bbox="297,448,515,693" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_2a65017d254e23f9.webp">
        <description>Clinical photo showing the intraoral view of a maxillary arch with a large, erythematous swelling on the hard palate adjacent to the upper teeth.</description>
      </img>
      <img order="2" bbox="576,313,913,711" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L5.2 Haematology 2 WBC_figures/img_c83c8fd61210cb7c.webp">
        <description>A composite panel of four axial medical imaging scans, likely CT and MRI sequences of the head and neck region. The images display cross-sectional anatomy including the maxillary sinuses, mandible, teeth, and brain structures, with visible hyperdense or hypointense lesions in the soft tissues of the face and jaw.</description>
      </img>
    </images>
  </page>
  <page number="55">
    <text># MULTIPLE MYELOMA
TREATMENT (OF RELEVANCE TO DENTISTRY)

**TREATMENT FOR CANCER**

*   Chemotherapy
*   Corticosteroids
*   Targeted therapy, immunotherapy, CAR-T cell therapy
    *   Thalidamide-derived agents (e.g. lenalidomide)
    *   Bortezomib
*   Stem cell / bone marrow transplant (typically autologous)
*   Radiotherapy (localised plasmacytic infiltration)

**TREATMENT FOR SYMPTOMS**
**(OF CANCER OR CANCER TREATMENT)**

*   Bisphosphonates
    *   Reduce bone pain
    *   Prevent pathological fracture
*   Anticoagulants
    *   Hyperviscosity of blood
    *   Lenalidomide – clotting tendency
*   Dialysis
    *   Renal failure</text>
    <formatted_text>#### Treatment for Cancer

- Chemotherapy
- Corticosteroids
- Targeted therapy, immunotherapy, CAR-T cell therapy
  - Thalidamide-derived agents (e.g. lenalidomide)
  - Bortezomib
- Stem cell / bone marrow transplant (typically autologous)
- Radiotherapy (localised plasmacytic infiltration)

#### Treatment for Symptoms (of Cancer or Cancer Treatment)

- Bisphosphonates
  - Reduce bone pain
  - Prevent pathological fracture
- Anticoagulants
  - Hyperviscosity of blood
  - Lenalidomide – clotting tendency
- Dialysis
  - Renal failure</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:43:46" confidence="5" anchor="Prevent pathological fracture">
    - ==Have implications because of medication-related osteonecrosis of the jaws.==</insert>
    </audio_inserts>
  </page>
  <page number="56">
    <text># DENTAL IMPLICATIONS</text>
  </page>
  <page number="57">
    <text># PRE-CANCER THERAPY DENTAL ASSESSMENT

*   Patients should have a comprehensive dental assessment prior to commencing chemotherapy or a stem cell / bone marrow transplant
    *   Comprehensive oral examination and xrays
*   Goal: identify indications for dental treatment before cancer therapy starts
    *   Infection
    *   Teeth with poor prognosis
    *   Potential causes of mucosal trauma (e.g. sharp teeth)
*   Institute appropriate oral care program (oral side effects of cancer therapy)
*   Dental interventions ideally completed before cancer therapy starts, but this may not be feasible
    *   Cancer therapy should not be delayed</text>
    <formatted_text>- Patients should have a comprehensive dental assessment prior to commencing chemotherapy or a stem cell / bone marrow transplant
  - Comprehensive oral examination and x-rays
- Goal: identify indications for dental treatment before cancer therapy starts
  - Infection
  - Teeth with poor prognosis
  - Potential causes of mucosal trauma (e.g. sharp teeth)
- Institute appropriate oral care program (oral side effects of cancer therapy)
- Dental interventions ideally completed before cancer therapy starts, but this may not be feasible
  - Cancer therapy should not be delayed</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:50:36" confidence="6" anchor="- Dental interventions ideally completed before cancer therapy starts, but this ">

&gt; [!note] Lecturer — Treatment Priorities
&gt; If time is limited, prioritise the most urgent and infection-prone dental problems first. Sometimes blood counts make dental treatment more hazardous than beneficial.
</insert>
    </audio_inserts>
  </page>
  <page number="58">
    <text>&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;DISEASE&lt;/th&gt;
    &lt;th&gt;TREATMENT&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• RBC: anaemia&lt;/td&gt;
    &lt;td&gt;• Chemotherapy: ↓ RBC/WBC/platelets, mucositis, hyposalivation, candidiasis, taste disturbances&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• WBC: infections&lt;/td&gt;
    &lt;td&gt;• Stem Cell / bone marrow transplant: ↓ RBC/WBC/platelets, mucositis, hyposalivation, candidiasis, HSV (cold sores), gingival hyperplasia (ciclosporin), dental developmental disturbances (paeds), GVHD (allo), SCC&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Platelets: bleeding&lt;/td&gt;
    &lt;td&gt;• Corticosteroids: adrenal suppression, fat redistribution, impaired wound healing, susceptibility infection, mood changes&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Hyperglobulinaemia / hypogammaglobulinaemia: infection [MM]&lt;/td&gt;
    &lt;td&gt;• Bisphosphonates [MM] + emerging targeted therapies: MRONJ&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;• Renal failure: dialysis [MM]&lt;/td&gt;
    &lt;td&gt;• Anticoagulants: bleeding [MM]&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;• Radiotherapy: mucositis, hyposalivation, candidiasis, increased caries risk, taste disturbances, osteoradionecrosis&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;</text>
    <formatted_text>#### Disease Effects

- RBC: anaemia
- WBC: infections
- Platelets: bleeding
- Hyperglobulinaemia / hypogammaglobulinaemia: infection [MM]
- Renal failure: dialysis [MM]

#### Treatment Effects

- Chemotherapy: ↓ RBC/WBC/platelets, mucositis, hyposalivation, candidiasis, taste disturbances
- Stem Cell / bone marrow transplant: ↓ RBC/WBC/platelets, mucositis, hyposalivation, candidiasis, HSV (cold sores), gingival hyperplasia (ciclosporin), dental developmental disturbances (paeds), GVHD (allo), SCC
- Corticosteroids: adrenal suppression, fat redistribution, impaired wound healing, susceptibility to infection, mood changes
- Bisphosphonates [MM] + emerging targeted therapies: MRONJ
- Anticoagulants: bleeding [MM]
- Radiotherapy: mucositis, hyposalivation, candidiasis, increased caries risk, taste disturbances, osteoradionecrosis</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:15:07" confidence="5" anchor="- Renal failure: dialysis [MM]">
- ==Malignancies may also cause mucosal ulceration, gingival enlargement or infiltration, bone pain, tooth mobility, paraesthesia, and pathological fractures.==</insert>
    </audio_inserts>
  </page>
  <page number="59">
    <text>DENTAL IMPLICATIONS (ACCESS)

Access
• Fatigue: time of day, may fatigue easily
• Timing of dental treatment: consult haematologist/oncologist
  • Defer elective treatment until remission phase
  • Dental pain: medical risks/timing weighed up against benefit of prompt dental treatment (usually infective source)
  • Chemotherapy: perform dental treatment day(s) before starting new cycle → chemotherapy nadir
  • [MM] Hemodialysis: book dental treatment on non-dialysis days (herparinisation)

![Myelosuppression following chemotherapy](L5.2 Haematology 2 WBC_figures/img_01246b8302708aad.webp)</text>
    <formatted_text>#### Fatigue

- Time of day considerations; may fatigue easily

#### Timing of Dental Treatment

- Consult haematologist/oncologist
  - Defer elective treatment until remission phase
  - Dental pain: medical risks/timing weighed up against benefit of prompt dental treatment (usually infective source)
  - Chemotherapy: perform dental treatment day(s) before starting new cycle → chemotherapy nadir
  - [MM] Haemodialysis: book dental treatment on non-dialysis days (heparinisation)</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:48:40" confidence="4" anchor="- Time of day considerations; may fatigue easily">

&gt; [!note] Lecturer — Managing Fatigue
&gt; Consider how much treatment the patient can tolerate in one visit. Shorter or modified appointments may be appropriate.
</insert>
      <insert timestamp="00:50:50" confidence="8" anchor="- Chemotherapy: perform dental treatment day(s) before starting new cycle → chem">

&gt; [!note] Lecturer — Chemotherapy Timing
&gt; The nadir generally occurs 7–14 days after treatment begins, when blood-cell counts are lowest and the risks of infection, anaemia, and bleeding increase.
&gt;
&gt; - Dental treatment is usually best timed toward the end of the cycle, when counts have recovered and before the next cycle.
&gt; - A blood test before the next cycle can help determine whether treatment is safe.
&gt; - For an extraction requiring about 10–14 days of healing, schedule it so healing occurs before the next nadir.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="583,387,929,718" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L5.2 Haematology 2 WBC_figures/img_01246b8302708aad.webp" caption="Myelosuppression following chemotherapy">
        <description>This is a schematic line chart titled 'Myelosuppression following chemotherapy' that illustrates the recovery of peripheral cell counts (specifically platelets and neutrophils) over time in days. The curve depicts a sharp decline from day 0 to a low point between days 7 and 14, which is bracketed and labelled as the 'Nadir', followed by a gradual return to normal levels by day 28.</description>
      </img>
    </images>
  </page>
  <page number="60">
    <text>DENTAL IMPLICATIONS (ACCESS)

Communication/Consent

• Usually no issues

• Visual disturbances (written material)

• Cognitive/neurological sequelae

• Setting expectations re: treatment approach</text>
    <formatted_text>- Usually no issues
- Visual disturbances (written material)
- Cognitive/neurological sequelae
- Setting expectations re: treatment approach</formatted_text>
  </page>
  <page number="61">
    <text>DENTAL IMPLICATIONS

Education / Prevention

**REVIEW ARTICLE**

Support Care Cancer (2015) 23:223–236
DOI 10.1007/s00520-014-2378-x

Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT)

Sharon Elad • Judith E. Raber-Durlacher • Michael T. Brennan • Deborah P. Saunders • Arno P. Mank • Yehuda Zadik • Barry Quinn • Joel B. Epstein • Nicole M. A. Bijllevens • Tuomas Wahlmio • Jakob R. Passweg • M. Elvira P. Correa • Göran Dahlöf • Karin U. E. Garming-Legert • Richard M. Logan • Carin M. J. Potting • Michael Y. Shapira • Yoshihiko Soga • Jacqui Stringer • Monique A. Stokman • Samuel Vokurka • Elisabeth Wallhult • Noam Yarom • Siri Beier Jensen

Received: 24 May 2014 / Accepted: 30 July 2014 / Published online: 5 September 2014
© Springer-Verlag Berlin Heidelberg 2014

Abstract
Purpose Hematology-oncology patients undergoing chemotherapy and hematopoietic stem cell transplantation (HSCT) recipients are at risk for oral complications which may cause significant morbidity and a potential risk of mortality. This emphasizes the importance of basic oral care prior to, during (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT) in attempt to provide guidance to the health care providers managing these patient populations.
Results The protocol on basic oral care outlined in this position paper is presented based on the following principles: prevention of infections, pain control, maintaining oral func-

RCS
British Society for
Disability and Oral Health

The Oral Management of
Oncology Patients
Requiring
Radiotherapy, Chemotherapy
and / or Bone Marrow
Transplantation

Clinical Guidelines

Updated 2018

The Royal College of Surgeons of England / The
British Society for Disability and Oral Health

Original Article

MASCC/ISOO Clinical Practice Guidelines for the Management
of Mucositis Secondary to Cancer Therapy

Sharon Elad, DMD, MSc$^1$; Karis Kin Fong Cheng, RN, PhD$^2$; Rajesh V. Lalla, DDS, PhD$^3$; Noam Yarom, DMD$^4$;
Catherine Hong, BDS, MS$^5$; Richard M. Logan, BDS, MDS, PhD$^{6,7}$; Joanne Bowen, PhD$^8$; Rachel Gibson, PhD$^9$;
Deborah P. Saunders, DDS$^{10}$; Yehuda Zadik, DMD, MHA$^{11,12}$; Anura Ariyawarnana, BDS, MS$^{13}$.
Maria Elvira Correa, DDS, PhD$^{14}$; Vrishla Ranma, DDS$^{15}$; and Paolo Bossi, MD$^{16}$; for the Mucositis Guidelines Leadership Group
of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO).

BACKGROUND: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. METHODS: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. RESULTS: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after a review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. CONCLUSIONS: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer. Cancer 2020;126:4423–4431. © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

KEYWORDS: cancer, gastrointestinal, guidelines, mucositis, Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO), oral.

INTRODUCTION
Mucositis is a common complication of radiotherapy (RT), chemotherapy (CT), a combination of RT and CT (RT-CT), and hematopoietic stem cell transplantation (HSCT). Mucositis is characterized by erythema and ulceration of the mucosal lining of the gastrointestinal (GI) tract. Oral mucositis (OM) is associated with pain, difficulty in

**MASCC/ISOO/EBMT 2015: Basic Oral Care for Haematology-Oncology Patients and HSCT Recipients position paper**

**Royal College of Surgeons England / BSDH 2018: Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and/or Bone Marrow Transplantation**

**MASCC/ISOO 2020: Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy**</text>
    <formatted_text>#### Key Guideline Sources

- MASCC/ISOO/EBMT 2015: Basic Oral Care for Haematology-Oncology Patients and HSCT Recipients position paper
- Royal College of Surgeons England / BSDH 2018: Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and/or Bone Marrow Transplantation
- MASCC/ISOO 2020: Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

#### Supporting Literature

*Elad, S., Raber-Durlacher, J. E., Brennan, M. T., Saunders, D. P., Mank, A. P., Zadik, Y., Quinn, B., Epstein, J. B., Bijllevens, N. M. A., Wahlmio, T., Passweg, J. R., Correa, M. E. P., Dahlöf, G., Garming-Legert, K. U. E., Logan, R. M., Potting, C. M. J., Shapira, M. Y., Soga, Y., Stringer, J., Stokman, M. A., Vokurka, S., Wallhult, E., Yarom, N., and Beier Jensen, S. (2015). Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT), Support Care Cancer, 23, 223–236.*

*Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., Ariyawarnana, A., Correa, M. E., Ranma, V., and Bossi, P., for the Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). (2020). MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy, Cancer, 126, 4423–4431.*

*Royal College of Surgeons of England / The British Society for Disability and Oral Health (2018). The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and / or Bone Marrow Transplantation — Clinical Guidelines, Updated 2018.*

The MASCC/ISOO 2020 guidelines cover evidence from 1197 publications related to oral or gastrointestinal mucositis; thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, 11 previous guidelines were confirmed after a review of new evidence, and 13 previously established guidelines were carried over because there was no new evidence for these interventions.</formatted_text>
  </page>
  <page number="62">
    <text>Prevention of infection
Before HSCT/CT
Oral/Dental examination
•Refer for dental evaluation
•Focus: Eliminate foci of infection, traumatic surfaces

During HSCT/CT
Oral hygiene
•Ensure cleaning teeth and tongue - soft bristled toothbrush - flossing if capable w/o trauma
Decontamination
•Advise using bland rinses (e.g., saline), repeated rinses/day
•Advise rinsing with chlorhexidine in alcohol free solution, x2/day
•If unable to rinse, apply solution to sterile gauze or toothette
Prophylaxis
•Apply the institute protocol for prophylaxis for oral candidiasis &amp; viral reactivation

After HSCT/CT
Viral infection
•Consider anti-viral prophylaxis
Candidal infection
•Consider anti-fungal prophylaxis: topical (sugar-free) or systemic
Dental infection
•Encourage the patient to have frequent dental recalls
Oral hygiene
•Educate &amp; reinforce optimal oral hygiene and dental prevention

Pain control
Prevention of local trauma
•Refer for dental evaluation
•Eliminate causes for local trauma

Pain assessment
•Score consistently (e.g., 0-10 scale/ WHO ladder)
Diagnosis
•Consult with an oral medicine / dentist for source of pain
Pain of dental origin
•Address using a non-surgical approach
Treatment
•Apply the institute protocol for pain control, topical &amp; systemic agents

Diagnosis
•Consult oral medicine / dentist for source of pain

Maintain oral function
Chewing capability
•Ask patient about difficulty to chew
•Refer to dentist to restore occlusion, if applicable

Speaking: Oral moisture
•Utilize:
- sugar free chewing gum/candy (non-acidic)
- dentifrices for oral dryness
- saliva substitute 1st line
- frequent sips of water

Diet
•Promote non-cariogenic, low acid atraumatic diet

Timing
•Consult physician / oral medicine specialist / dentist for best timing for routine dental treatment &amp; any prophylactic measures

Managing oral complications of the underlying cancer or anti-cancer treatment
Oral examination
•Refer for an oral medicine specialist / dentist

Detection
•Detect possible signs &amp; symptoms
•Consult with oral medicine specialist / dentist treatment

Dry Mouth
• Maintain good oral hygiene
- use fluoride supplements
- avoid sweets
- visit the dentist regularly

Limited mouth opening
•Consider physiotherapy
•Motivate routine dental care
•Encourage oral hygiene

cGVHD (mucosa, salivary gland)
•Consult with an oral medicine specialist / dentist for current treatment recommendations
•Motivate patient to keep routine surveillance (risk for SCC)

Quality of life
Education
•Inform about future possible oral complications

Taste change
•Encourage the patient to maintain oral intake

Dry Mouth
•Utilize:
- sugar free chewing gum/candy (non-acidic)
- dentifrices for oral dryness
- saliva substitute
- frequent sips of water

Awareness of future dental problems
•Educate patient regarding late effects of therapy

Dry Mouth
•Motivate patients to:
- keep oral hygiene
- use fluoride supplements
- avoid sweets
- visit the dentist regularly
•Utilize:
- sialogogues
- sugar free chewing gum/candy (non-acidic)
- saliva substitute for palliation
- frequent sips of water

MASCC/ISOO/EBMT 2015: Basic Oral Care for Haematology-Oncology Patients and HSCT Recipients position paper

![Fig. 1 HSCT haematopoietic stem cells transplantation, CT chemotherapy, WHO world health organization, cGVHD chronic graft versus host disease, SCC squamous cell carcinoma](L5.2 Haematology 2 WBC_figures/img_fc60260198615bf6.webp)</text>
    <formatted_text>#### Prevention of Infection

*Before HSCT/CT — Oral/Dental examination*

- Refer for dental evaluation
- Focus: eliminate foci of infection, traumatic surfaces

*During HSCT/CT*

- Oral hygiene: ensure cleaning teeth and tongue — soft bristled toothbrush — flossing if capable without trauma
- Decontamination:
  - Advise using bland rinses (e.g., saline), repeated rinses/day
  - Advise rinsing with chlorhexidine in alcohol-free solution, x2/day
  - If unable to rinse, apply solution to sterile gauze or toothette
- Prophylaxis: apply the institute protocol for prophylaxis for oral candidiasis and viral reactivation

*After HSCT/CT*

- Viral infection: consider anti-viral prophylaxis
- Candidal infection: consider anti-fungal prophylaxis — topical (sugar-free) or systemic
- Dental infection: encourage the patient to have frequent dental recalls
- Oral hygiene: educate and reinforce optimal oral hygiene and dental prevention

#### Pain Control

- Prevention of local trauma: refer for dental evaluation; eliminate causes for local trauma
- Pain assessment: score consistently (e.g., 0–10 scale / WHO ladder)
- Diagnosis: consult with an oral medicine specialist / dentist for source of pain
- Pain of dental origin: address using a non-surgical approach
- Treatment: apply the institute protocol for pain control, topical and systemic agents

#### Maintain Oral Function

- Chewing capability: ask patient about difficulty to chew; refer to dentist to restore occlusion, if applicable
- Speaking / oral moisture — utilize:
  - Sugar-free chewing gum/candy (non-acidic)
  - Dentifrices for oral dryness
  - Saliva substitute (first line)
  - Frequent sips of water
- Diet: promote non-cariogenic, low acid, atraumatic diet
- Timing: consult physician / oral medicine specialist / dentist for best timing for routine dental treatment and any prophylactic measures

#### Managing Oral Complications of the Underlying Cancer or Anti-Cancer Treatment

- Oral examination: refer to an oral medicine specialist / dentist
- Detection: detect possible signs and symptoms; consult with oral medicine specialist / dentist re: treatment
- Dry mouth:
  - Maintain good oral hygiene
  - Use fluoride supplements
  - Avoid sweets
  - Visit the dentist regularly
- Limited mouth opening: consider physiotherapy; motivate routine dental care; encourage oral hygiene
- cGVHD (mucosa, salivary gland): consult with an oral medicine specialist / dentist for current treatment recommendations; motivate patient to keep routine surveillance (risk for SCC)

#### Quality of Life

- Education: inform about future possible oral complications; educate patient regarding late effects of therapy
- Taste change: encourage the patient to maintain oral intake
- Dry mouth:
  - Motivate patients to keep oral hygiene, use fluoride supplements, avoid sweets, visit the dentist regularly
  - Utilize sialogogues, sugar-free chewing gum/candy (non-acidic), saliva substitute for palliation, frequent sips of water

*Source: MASCC/ISOO/EBMT 2015: Basic Oral Care for Haematology-Oncology Patients and HSCT Recipients position paper*</formatted_text>
    <images>
      <img order="0" bbox="146,160,871,771" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L5.2 Haematology 2 WBC_figures/img_fc60260198615bf6.webp" caption="Fig. 1 HSCT haematopoietic stem cells transplantation, CT chemotherapy, WHO world health organization, cGVHD chronic graft versus host disease, SCC squamous cell carcinoma">
        <description>A structured flowchart organizing oral care guidelines for haematology-oncology patients and HSCT recipients. The diagram is divided into five vertical columns representing key management areas (Prevention of infection, Pain control, Maintain oral function, Managing oral complications, and Quality of life) and three horizontal rows corresponding to treatment phases: Before HSCT/CT, During HSCT/CT, and After HSCT/CT.</description>
      </img>
    </images>
  </page>
  <page number="63">
    <text>DENTAL IMPLICATIONS

Education / Prevention

• Counsel on possible oral side effects of chemotherapy
    • Each chemotherapy agent has different adverse effects
    • Common examples: mucositis, reduced salivary flow, immune suppression
• Increase risk of oral infections: oral and oropharyngeal candidiasis, herpes simplex virus, post-operative infection

![](L5.2 Haematology 2 WBC_figures/img_394706d5f443c838.webp)
![](L5.2 Haematology 2 WBC_figures/img_269b4ff4c5c4d102.webp)
![](L5.2 Haematology 2 WBC_figures/img_466852af1c15c890.webp)
![](L5.2 Haematology 2 WBC_figures/img_3b0c0265d6fa2845.webp)</text>
    <formatted_text>- Counsel on possible oral side effects of chemotherapy
  - Each chemotherapy agent has different adverse effects
  - Common examples: mucositis, reduced salivary flow, immune suppression
- Increased risk of oral infections: oral and oropharyngeal candidiasis, herpes simplex virus, post-operative infection</formatted_text>
    <images>
      <img order="0" bbox="153,631,329,799" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_394706d5f443c838.webp">
        <description>Clinical photograph showing a close-up of the lower face, specifically the mouth area. A distinct reddish lesion with some crusting is visible on the vermilion border of the upper lip at the corner of the mouth (commissure), illustrating an oral infection or side effect.</description>
      </img>
      <img order="1" bbox="391,632,583,799" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_269b4ff4c5c4d102.webp">
        <description>Clinical photograph showing the posterior oral cavity, including the soft palate and tonsillar pillars. The mucosal surfaces display multiple scattered, irregular white plaques or patches consistent with oral candidiasis.</description>
      </img>
      <img order="2" bbox="763,238,940,410" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_466852af1c15c890.webp">
        <description>Clinical photograph showing the ventral surface of a tongue with visible mucosal lesions.</description>
      </img>
      <img order="3" bbox="660,452,940,633" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_3b0c0265d6fa2845.webp">
        <description>Two clinical photographs of the oral cavity, labelled 2 and 3. Image 2 shows the dorsal surface of a tongue with prominent fissures (fissured tongue). Image 3 displays the floor of the mouth and the ventral aspect of the tongue, showing the lingual frenulum.</description>
      </img>
    </images>
  </page>
  <page number="64">
    <text>DENTAL IMPLICATIONS

Education / Prevention

• Chemotherapy / radiotherapy / HSCT
    • Pain:
        • Encourage compliance with oral hygiene (brush 2-3 times/day)
        • Suck ice chips 30min prior to chemotherapy
        • Topical anaesthetics: xylocaine viscous, Seda Lotion
        • Surgical ultra-soft toothbrush (Curaprox)
            • Air-dry between uses
            • Sponge brushes better than nothing, but not as effective
    • SLS-free toothpaste (e.g. Oral 7, Biotene)
    • Avoid spicy/rough/crunchy/acidic food and drinks

• Hyposalivation:
    • Caries risk (buffering capacity; food stagnation; modified diet)
    • Bicarb + salt mouthrinses after meals
    • Saliva substitutes (e.g. Oral 7, Biotene gel, MW, spray)
    • Regular lip balm
    • Oral 7 gel for denture retention

![](L5.2 Haematology 2 WBC_figures/img_3f538149c6b21ac8.webp)
![](L5.2 Haematology 2 WBC_figures/img_4593fbb374044200.webp)
![](L5.2 Haematology 2 WBC_figures/img_9fd3e4590f11fb52.webp)
![](L5.2 Haematology 2 WBC_figures/img_5b2f24104b78dd8a.webp)
![](L5.2 Haematology 2 WBC_figures/img_ec4221c934bdcf9b.webp)</text>
    <formatted_text>#### Chemotherapy / Radiotherapy / HSCT — Pain

- Encourage compliance with oral hygiene (brush 2–3 times/day)
- Suck ice chips 30 min prior to chemotherapy
- Topical anaesthetics: xylocaine viscous, Seda Lotion
- Surgical ultra-soft toothbrush (Curaprox)
  - Air-dry between uses
  - Sponge brushes better than nothing, but not as effective
- SLS-free toothpaste (e.g. Oral 7, Biotene)
- Avoid spicy/rough/crunchy/acidic food and drinks

#### Hyposalivation

- Caries risk (buffering capacity; food stagnation; modified diet)
- Bicarb + salt mouthrinses after meals
- Saliva substitutes (e.g. Oral 7, Biotene gel, MW, spray)
- Regular lip balm
- Oral 7 gel for denture retention</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:57:31" confidence="5" anchor="- Avoid spicy/rough/crunchy/acidic food and drinks">
- ==A bland rinse can be made with half a teaspoon of salt and half a teaspoon of bicarbonate of soda in a glass of water, and used as often as required.==</insert>
      <insert timestamp="00:56:55" confidence="8" anchor="- Regular lip balm">
- ==Plant-based or animal-derived lip products were preferred over petroleum-based products because petroleum-based products do not moisturise the lips.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="495,299,587,589" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_3f538149c6b21ac8.webp">
        <description>A bottle of Xylocaine Viscous, a pharmacy medicine used for topical anaesthesia of the mouth and upper gastrointestinal tract.</description>
      </img>
      <img order="1" bbox="623,305,706,521" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_4593fbb374044200.webp">
        <description>A photograph of a packaging box for Seda Lotion, a pharmacy medicine containing 2.5% w/v Lidocaine (lignocaine) in Raspberry Flavour. The label indicates it relieves pain from mouth ulcers, toothache, and sore gums.</description>
      </img>
      <img order="2" bbox="618,557,686,796" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L5.2 Haematology 2 WBC_figures/img_9fd3e4590f11fb52.webp">
        <description>The image shows the packaging for Oral7 toothpaste, featuring a central illustration of a tooth with roots surrounded by pink gum tissue. Green arrows depict liquid flowing over and around the tooth to simulate saliva action, accompanied by text highlighting &quot;Real Dry Mouth Relief&quot; and ingredients like fluoride, calcium, and active enzymes.</description>
      </img>
      <img order="3" bbox="739,308,805,737" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_5b2f24104b78dd8a.webp">
        <description>Product photograph of a red Curaprox surgical toothbrush in its retail blister packaging. The package features the brand name &quot;CURAPROX&quot; and the label &quot;surgical&quot; alongside the tagline &quot;Swiss Premium Oral Care&quot;.</description>
      </img>
      <img order="4" bbox="841,339,947,684" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_ec4221c934bdcf9b.webp">
        <description>A product photograph showing a sealed, foil-backed packet of Oraswaf mouth swabs on the left and a single unwrapped sponge-tipped applicator standing vertically on the right. The packaging features a red circular logo and purple branding text, while the applicator consists of a clear plastic handle with a blue, ribbed foam head.</description>
      </img>
    </images>
  </page>
  <page number="65">
    <text>DENTAL IMPLICATIONS
Education / Prevention

• Chemotherapy / radiotherapy / HSCT
• Opportunistic infections (candida, periodontal pathogens, suprainfection of mucositis)
  • Maintain oral hygiene
  • Alcohol-free chlorhexidine rinse
    • add as short-term oral antiseptic if oral hygiene compromised
    • 0.2% ideal, substantivity at 0.1% (dilute 50:50 with water)
  • Bland rinses
  • Denture hygiene
• Flossing?
  • “Measures to remove plaque from between teeth, crown &amp; bridges or implants, and from tongue, should be continued using familiar devices to pt to avoid self-injury”
  • History of regular interdental cleaning? Or raging gingivitis?

MASCC/ISOO/EBMT 2015: Basic Oral Care for Haematology-Oncology Patients and HSCT Recipients position paper

![](L5.2 Haematology 2 WBC_figures/img_ddb86e685d7d44de.webp)
![](L5.2 Haematology 2 WBC_figures/img_2b8be8e02d408ac7.webp)</text>
    <formatted_text>#### Chemotherapy / Radiotherapy / HSCT — Opportunistic Infections

Opportunistic infections (candida, periodontal pathogens, suprainfection of mucositis):

- Maintain oral hygiene
- Alcohol-free chlorhexidine rinse
  - Add as short-term oral antiseptic if oral hygiene compromised
  - 0.2% ideal, substantivity at 0.1% (dilute 50:50 with water)
- Bland rinses
- Denture hygiene

#### Flossing?

&gt; &quot;Measures to remove plaque from between teeth, crown &amp; bridges or implants, and from tongue, should be continued using familiar devices to patient to avoid self-injury&quot;

- History of regular interdental cleaning? Or raging gingivitis?

*Source: MASCC/ISOO/EBMT 2015: Basic Oral Care for Haematology-Oncology Patients and HSCT Recipients position paper*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:00:07" confidence="5" anchor="*Source: MASCC/ISOO/EBMT 2015: Basic Oral Care for Haematology-Oncology Patients">

&gt; [!note] Lecturer — Individualised Flossing
&gt; Flossing recommendations should be individualised according to platelet count, immunosuppression, gingival health, and familiarity with flossing.
&gt;
&gt; - Some centres advise no flossing during stem-cell transplantation or severe thrombocytopenia.
&gt; - Regular flossers with good gingival health may benefit from continuing, whereas starting flossing during severe gingivitis is inappropriate.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="657,190,966,450" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_ddb86e685d7d44de.webp">
        <description>A product photograph displaying two sets of Curasept brand oral rinse packaging and bottles. The items shown are the ADS 220 (Chlorhexidine 0.20) and ADS 212 (Chlorhexidine 0.12), both explicitly labeled as &quot;NO ALCOHOL&quot;.</description>
      </img>
      <img order="1" bbox="766,509,896,727" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_2b8be8e02d408ac7.webp">
        <description>A product shot of a white and blue box of McKenzie's Bi-Carb Soda (Baking Soda), showing the brand logo, net weight, and origin details.</description>
      </img>
    </images>
  </page>
  <page number="66">
    <text>DENTAL IMPLICATIONS

Surgery

• RBC (anaemia):
  • Check Hb levels prior to appointment– caution &lt;80 g/L
  • Desaturation – stress of dental procedure
  • Consider pulse oximetry, nasal oxygen, RBC transfusioin
  • Pallor, atrophic glossitis, angular cheilitis, ulcers, glossodynia

• Platelets (bleeding)
  • Ideally check within 24hrs of dental procedure – caution &lt;50 x 10⁹/L
  • Consider platelet transfusion – rapid sequestration
  • Caution regional LA blocks and lingual infiltrations
  • Consider cushioning retraction instruments during extractions
  • Lip emollient to prevent cracking/bleeding
  • Local haemostatic measures post-extractions

Check bloods ➔ Consider specialist setting if deranged</text>
    <formatted_text>#### RBC (Anaemia)

- Check Hb levels prior to appointment — caution &lt;80 g/L
- Desaturation — stress of dental procedure
- Consider pulse oximetry, nasal oxygen, RBC transfusion
- Pallor, atrophic glossitis, angular cheilitis, ulcers, glossodynia

#### Platelets (Bleeding)

- Ideally check within 24 hrs of dental procedure — caution &lt;50 x 10⁹/L
- Consider platelet transfusion — rapid sequestration
- Caution regional LA blocks and lingual infiltrations
- Consider cushioning retraction instruments during extractions
- Lip emollient to prevent cracking/bleeding
- Local haemostatic measures post-extractions

&gt; Check bloods → Consider specialist setting if deranged</formatted_text>
  </page>
  <page number="67">
    <text># DENTAL IMPLICATIONS

Surgery

*   WBC (infections):
    *   Ideally check counts within 24hrs of dental procedures
    *   WBC: caution &lt;3 x 10⁹/L, need to see profiling
    *   Neutrophils: &lt;1 x 10⁹/L – risks of infection, poor wound healing, bacteraemia.
        *   Liaise with haematologist/oncologist to support haematologically (e.g. G-CSF)
        *   Surgical gown and sterile environment/equipment
        *   Consider post-op 1 wk chlorhexidine rinse
        *   Consider antibiotic prophylaxis.
*   Aerosol-generating procedures (e.g. S/C with u/s scaler) should be minimised if immunosuppressed immediately post-CT/HSCT

Check bloods ➡ Consider specialist setting if deranged</text>
    <formatted_text>#### WBC (Infections)

- Ideally check counts within 24 hrs of dental procedures
- WBC: caution &lt;3 x 10⁹/L, need to see profiling
- Neutrophils: &lt;1 x 10⁹/L — risks of infection, poor wound healing, bacteraemia
  - Liaise with haematologist/oncologist to support haematologically (e.g. G-CSF)
  - Surgical gown and sterile environment/equipment
  - Consider post-op 1 wk chlorhexidine rinse
  - Consider antibiotic prophylaxis

#### Aerosol-Generating Procedures

- Aerosol-generating procedures (e.g. S/C with u/s scaler) should be minimised if immunosuppressed immediately post-CT/HSCT

&gt; Check bloods → Consider specialist setting if deranged</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:04:14" confidence="4" anchor="- Aerosol-generating procedures (e.g. S/C with u/s scaler) should be minimised i">

&gt; [!note] Lecturer — Aerosol Risk
&gt; Plaque contains bacteria, so aerosolising substantial plaque in severely immunosuppressed patients may increase bacterial exposure and pneumonia risk.
</insert>
    </audio_inserts>
  </page>
  <page number="68">
    <text>DENTAL
IMPLICATIONS

Therapeutic
Guidelines – Oral
and Dental v4 2026

**Immune compromise: dental considerations**

🌐 Oral and Dental

**Immune compromise: dental considerations**

A patient’s degree of immune compromise affects treatment decisions, including decisions on indications for antibiotic treatment of established infection or prophylaxis for a dental procedure.

Patients with profound immune compromise are at increased risk of infection which can spread rapidly. Their dental management requires a multidisciplinary approach that considers **how invasive a procedure is and the associated risk of infection**.

Risk of bleeding also requires evaluation because patients may have impaired haemostasis.

Causes of profound immune compromise include:

*   kidney failure (end-stage kidney disease)
*   liver failure (end-stage liver disease)
*   active haematological malignancies (leukaemias, lymphomas, myelomas)
*   some chemotherapies and immunotherapies (eg Chimeric Antigen Receptor T-Cell therapy [CAR T-cell therapy]) for malignancies, particularly for leukaemia and lymphoma
*   immune suppressive drugs for peripheral blood stem cell and bone marrow transplants
*   immune suppressive drugs for solid organ transplantation or autoimmune and inflammatory conditions (eg rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus, vasculitides)
*   untreated or end-stage human immunodeficiency virus (HIV) infection
*   primary immunodeficiency syndromes; see this guideline from the Royal Children's Hospital for features of these syndromes.

Not all immune compromise is profound. For example, suboptimally managed diabetes can compromise the immune system but is not a cause of profound immune compromise that may warrant broader indications for antibiotic use (than apply to patients who are immunocompetent). Parameters that can guide medical practitioners in assessing the severity of immune suppression include:

*   a low neutrophil count – severe neutropenia is a manifestation of profound immunosuppression in many of the conditions listed above
*   reduced antibody production (hypogammaglobulinaemia) (eg in patients with myeloma or lymphoma)
*   other immune parameters (eg CD4 cell counts).

If a patient has a condition that may cause profound immune compromise, consult the patient’s medical practitioner, specialist or multidisciplinary team to assess the severity of the immune compromise, and to determine an appropriate treatment plan (eg treatment for established infection, decisions on surgical antibiotic prophylaxis, assessment and management of bleeding risk). For classification of dental procedures by invasiveness and implications for risk management, see Table 13.29.</text>
    <formatted_text>*Therapeutic Guidelines – Oral and Dental v4 2026*

A patient's degree of immune compromise affects treatment decisions, including decisions on indications for antibiotic treatment of established infection or prophylaxis for a dental procedure.

Patients with profound immune compromise are at increased risk of infection which can spread rapidly. Their dental management requires a multidisciplinary approach that considers **how invasive a procedure is and the associated risk of infection**.

Risk of bleeding also requires evaluation because patients may have impaired haemostasis.

#### Causes of Profound Immune Compromise

- Kidney failure (end-stage kidney disease)
- Liver failure (end-stage liver disease)
- Active haematological malignancies (leukaemias, lymphomas, myelomas)
- Some chemotherapies and immunotherapies (e.g. Chimeric Antigen Receptor T-Cell therapy [CAR T-cell therapy]) for malignancies, particularly for leukaemia and lymphoma
- Immune suppressive drugs for peripheral blood stem cell and bone marrow transplants
- Immune suppressive drugs for solid organ transplantation or autoimmune and inflammatory conditions (e.g. rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus, vasculitides)
- Untreated or end-stage human immunodeficiency virus (HIV) infection
- Primary immunodeficiency syndromes (see the Royal Children's Hospital guideline for features of these syndromes)

#### Assessing Severity of Immune Suppression

Not all immune compromise is profound. For example, suboptimally managed diabetes can compromise the immune system but is not a cause of profound immune compromise that may warrant broader indications for antibiotic use (than apply to patients who are immunocompetent). Parameters that can guide medical practitioners in assessing the severity of immune suppression include:

- A low neutrophil count — severe neutropenia is a manifestation of profound immunosuppression in many of the conditions listed above
- Reduced antibody production (hypogammaglobulinaemia) (e.g. in patients with myeloma or lymphoma)
- Other immune parameters (e.g. CD4 cell counts)

If a patient has a condition that may cause profound immune compromise, consult the patient's medical practitioner, specialist or multidisciplinary team to assess the severity of the immune compromise, and to determine an appropriate treatment plan (e.g. treatment for established infection, decisions on surgical antibiotic prophylaxis, assessment and management of bleeding risk). For classification of dental procedures by invasiveness and implications for risk management, see Table 13.29.</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="01:13:06" confidence="7" anchor="If a patient has a condition that may cause profound immune compromise, consult ">

&gt; [!note] Lecturer — Prophylaxis Decisions
&gt; The choice of antibiotic may require discussion when the patient is already taking background antibiotics. Local infection also matters: extracting a tooth with a large periapical lesion introduces an infected site into the bloodstream.
</insert>
      <insert timestamp="01:08:46" confidence="6" anchor="#### **Determining Risk of Adrenal Crisis**  1. Patient factors 2. Procedural fa">

&gt; [!note] Lecturer — Adrenal Crisis
&gt; Adrenal crisis is life-threatening and may occur during physiological stress from a dental procedure. Symptoms can include abdominal pain, vomiting, diarrhoea, hypotension, confusion, and acute circulatory failure.
</insert>
      <insert timestamp="01:12:56" confidence="3" anchor="## **Questions and Contact**  **QUESTIONS?**">

&gt; [!note] Lecturer — Antibiotic Consultation
&gt; Antibiotic prophylaxis should be assessed jointly by the dentist and medical team. The dentist should explain the anticipated bacteraemia risk, particularly when the choice of antibiotic is uncertain or the patient is already taking background antibiotics.
</insert>
    </audio_inserts>
  </page>
  <page number="69">
    <text>DENTAL IMPLICATIONS

**Indications for surgical antibiotic prophylaxis in dentistry**

Recommendations on surgical antibiotic prophylaxis involve evaluating the efficacy of antibiotics in reducing postoperative infections (for specific procedures and patient groups) against the risk of harms. Potential harms of antimicrobial use include diarrhoea, &lt;u&gt;hypersensitivity reactions&lt;/u&gt; and bacterial resistance; for more detail, see discussion of &lt;u&gt;adverse effects of antimicrobials&lt;/u&gt; and &lt;u&gt;the importance of antimicrobial stewardship&lt;/u&gt;.

In **patients without profound immune compromise**, surgical antibiotic prophylaxis is indicated for some oral and maxillofacial surgical procedures, but not for most other dental procedures because the potential benefit is outweighed by potential harms. For a summary of which procedures require surgical prophylaxis and which do not, see Table 13.12.

In **patients with &lt;u&gt;profound immune compromise&lt;/u&gt;**, the need to consider broader indications for surgical antibiotic prophylaxis (than for patients with intact immune function) is uncertain because evidence of the balance of benefits and harms is lacking. Consider &lt;u&gt;consulting the treating specialist&lt;/u&gt; or multidisciplinary team about surgical antibiotic prophylaxis in patients with profound immune compromise[3][2]; for examples of &lt;u&gt;relevant dental&lt;/u&gt; procedures, see Table 13.29.

Surgical antibiotic prophylaxis is rarely indicated for dental procedures.

Therapeutic
Guidelines – Oral
and Dental v4 2026</text>
    <formatted_text>*Therapeutic Guidelines – Oral and Dental v4 2026*

Recommendations on surgical antibiotic prophylaxis involve evaluating the efficacy of antibiotics in reducing postoperative infections (for specific procedures and patient groups) against the risk of harms. Potential harms of antimicrobial use include diarrhoea, hypersensitivity reactions and bacterial resistance.

- In **patients without profound immune compromise**, surgical antibiotic prophylaxis is indicated for some oral and maxillofacial surgical procedures, but not for most other dental procedures because the potential benefit is outweighed by potential harms (see Table 13.12 for a summary of which procedures require surgical prophylaxis and which do not).
- In **patients with profound immune compromise**, the need to consider broader indications for surgical antibiotic prophylaxis (than for patients with intact immune function) is uncertain because evidence of the balance of benefits and harms is lacking. Consider consulting the treating specialist or multidisciplinary team about surgical antibiotic prophylaxis in patients with profound immune compromise; for examples of relevant dental procedures, see Table 13.29.

&gt; Surgical antibiotic prophylaxis is rarely indicated for dental procedures.</formatted_text>
  </page>
  <page number="70">
    <text>DENTAL IMPLICATIONS

**Therapeutic Guidelines – Oral and Dental v4 2026**

Table 13.29 Classification of dental procedures by invasiveness and considerations for risk management
Printable table
noninvasive procedures
minimally invasive procedures
* gingival retraction cord, subgingival matrix band placement, stainless steel crowns, rubber dam clamps
* supragingival debridement
* dental restorations requiring local anaesthetic or closed root canal procedure
invasive procedures

| minimally invasive procedures: supragingival debridement | | | |
| :--- | :--- | :--- | :--- |
| **bleeding risk considerations** | **antibiotic prophylaxis** | **other considerations** | |
| unlikely to cause prolonged bleeding, but see Table 13.30 for considerations to minimise risk | surgical antibiotic prophylaxis is not required for most patients; consider (with the patient's medical team) whether it is appropriate for patients with gingivitis and profound immune compromise&lt;br&gt;infective endocarditis prophylaxis is indicated in patients with specific cardiac conditions | an increase in glucocorticoid replacement is not indicated for patients at risk of adrenal crisis | |

| invasive procedures | | | |
| :--- | :--- | :--- | :--- |
| tooth extraction, periodontal surgery, biopsies, implant placement, subgingival debridement | | | |
| **bleeding risk considerations** | **antibiotic prophylaxis** | **other considerations** | |
| prolonged bleeding is likely with invasive procedures; see Table 13.30 for considerations to minimise risk | for patients without profound immune compromise, surgical antibiotic prophylaxis is not indicated for most dental procedures; see Table 13.12&lt;br&gt;for patients with profound immune compromise, consider (with the patient's medical team) whether surgical antibiotic prophylaxis is appropriate&lt;br&gt;infective endocarditis prophylaxis is recommended only for specific oral and dental procedures in patients with specific cardiac conditions | an increase in glucocorticoid dose is recommended in patients at risk of adrenal crisis (including patients on chronic glucocorticoids [eg prednisolone 5 mg or more daily for more than 3 weeks]); seek advice from the patient's medical practitioner&lt;br&gt;risk of triggering medication-related osteonecrosis of the jaw (MRONJ) may be increased for patients taking certain medications | |

![tooth extraction, periodontal surgery, biopsies, implant placement, subgingival debridement](L5.2 Haematology 2 WBC_figures/img_5706a7809233e9c4.webp)
![](L5.2 Haematology 2 WBC_figures/img_88b42dedbac7cf6c.webp)</text>
    <formatted_text>*Therapeutic Guidelines – Oral and Dental v4 2026*

#### Table 13.29: Classification of Dental Procedures by Invasiveness and Considerations for Risk Management

**Noninvasive procedures**

**Minimally invasive procedures:** gingival retraction cord, subgingival matrix band placement, stainless steel crowns, rubber dam clamps; supragingival debridement; dental restorations requiring local anaesthetic or closed root canal procedure

- Bleeding risk considerations: unlikely to cause prolonged bleeding, but see Table 13.30 for considerations to minimise risk
- Antibiotic prophylaxis: surgical antibiotic prophylaxis is not required for most patients; consider (with the patient's medical team) whether it is appropriate for patients with gingivitis and profound immune compromise; infective endocarditis prophylaxis is indicated in patients with specific cardiac conditions
- Other considerations: an increase in glucocorticoid replacement is not indicated for patients at risk of adrenal crisis

**Invasive procedures:** tooth extraction, periodontal surgery, biopsies, implant placement, subgingival debridement

- Bleeding risk considerations: prolonged bleeding is likely with invasive procedures; see Table 13.30 for considerations to minimise risk
- Antibiotic prophylaxis: for patients without profound immune compromise, surgical antibiotic prophylaxis is not indicated for most dental procedures (see Table 13.12); for patients with profound immune compromise, consider (with the patient's medical team) whether surgical antibiotic prophylaxis is appropriate; infective endocarditis prophylaxis is recommended only for specific oral and dental procedures in patients with specific cardiac conditions
- Other considerations: an increase in glucocorticoid dose is recommended in patients at risk of adrenal crisis (including patients on chronic glucocorticoids [e.g. prednisolone 5 mg or more daily for more than 3 weeks]); seek advice from the patient's medical practitioner; risk of triggering medication-related osteonecrosis of the jaw (MRONJ) may be increased for patients taking certain medications</formatted_text>
    <images>
      <img order="0" bbox="70,490,938,613" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_5706a7809233e9c4.webp" caption="tooth extraction, periodontal surgery, biopsies, implant placement, subgingival debridement">
        <description>This is a table row detailing the risk management considerations for minimally invasive dental procedures. The columns specify guidelines for bleeding risk, antibiotic prophylaxis, and other considerations, such as glucocorticoid replacement.</description>
      </img>
      <img order="1" bbox="70,682,938,819" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_88b42dedbac7cf6c.webp">
        <description>A table row detailing risk management considerations for invasive dental procedures, with columns for bleeding risk, antibiotic prophylaxis, and other considerations. Specific text regarding surgical antibiotic prophylaxis for patients with profound immune compromise is underlined in red.</description>
      </img>
    </images>
  </page>
  <page number="71">
    <text># DENTAL IMPLICATIONS

**Surgery**

*   Bisphosphonates [MM] and emerging targeted therapies
    *   MRONJ (coming up soon!)
    *   Well-fitting dentures
    *   Consider if possible to avoid extraction (treat periodontally, endodontically)
*   Antithrombotic therapy [MM]
    *   Invasive dental procedures
    *   Consult with haematologist/oncologist, since MM-induced thrombocytopenia, chemotherapy and antithrombotic drugs all contribute to bleeding risk
    *   Consider withholding just prior to dental procedure (separate lecture - *Haemostasis*)</text>
    <formatted_text>#### Bisphosphonates [MM] and Emerging Targeted Therapies

- MRONJ (coming up soon!)
- Well-fitting dentures
- Consider if possible to avoid extraction (treat periodontally, endodontically)

#### Antithrombotic Therapy [MM]

- Invasive dental procedures
- Consult with haematologist/oncologist, since MM-induced thrombocytopenia, chemotherapy and antithrombotic drugs all contribute to bleeding risk
- Consider withholding just prior to dental procedure (separate lecture — *Haemostasis*)</formatted_text>
  </page>
  <page number="72">
    <text>DENTAL IMPLICATIONS

**\*Therapeutic Guidelines – Oral and Dental v4 2026**

Surgery

• Corticosteroids
    • Adrenal crisis – physiological stress/anxiety from dental procedure
    • Risk of adrenal suppression depends on dose, duration, potency and route of administration of glucocorticoid, individual susceptibility
    • \*Oral prednisolone &gt;5mg daily for &gt;3 weeks
    • Multiple corticosteroid formulations concurrently (e.g. inhaled and oral)

• Determining risk of adrenal crisis:
    • 1) Patient factors
    • 2) Procedural factors</text>
    <formatted_text>*Therapeutic Guidelines – Oral and Dental v4 2026*

#### Corticosteroids

- Adrenal crisis — physiological stress/anxiety from dental procedure
- Risk of adrenal suppression depends on dose, duration, potency and route of administration of glucocorticoid, individual susceptibility
- Oral prednisolone &gt;5 mg daily for &gt;3 weeks
- Multiple corticosteroid formulations concurrently (e.g. inhaled and oral)

#### Determining Risk of Adrenal Crisis

1. Patient factors
2. Procedural factors</formatted_text>
  </page>
  <page number="73">
    <text>DENTAL IMPLICATIONS
Therapeutic Guidelines – Oral and Dental v4 2026

| minimally invasive procedures: dental restorations requiring local anaesthetic or closed (nonsurgical) root canal procedure | | |
| :--- | :--- | :--- |
| **bleeding risk considerations** | **antibiotic prophylaxis** | **other considerations** |
| unlikely to cause prolonged bleeding if local infiltration alone is used; if an inferior alveolar nerve block is required, see Table 13.30 for considerations to minimise risk | surgical antibiotic prophylaxis is not indicated&lt;br&gt;infective endocarditis prophylaxis is not indicated | an increase in glucocorticoid dose is recommended for &lt;u&gt;patients at risk of adrenal crisis&lt;/u&gt; (including patients on chronic glucocorticoids [eg prednisolone 5 mg or more daily for more than 3 weeks]); seek advice from the patient’s medical practitioner [NB4] |
| **invasive procedures** | | |
| tooth extraction, periodontal surgery, biopsies, implant placement, subgingival debridement | | |
| **bleeding risk considerations** | **antibiotic prophylaxis** | **other considerations** |
| prolonged bleeding is likely with invasive procedures; see Table 13.30 for considerations to minimise risk | for patients **without profound immune compromise**, surgical antibiotic prophylaxis is not indicated for most dental procedures; see Table 13.12&lt;br&gt;&lt;br&gt;for patients **with profound immune compromise**, consider (with the patient’s medical team) whether surgical antibiotic prophylaxis is appropriate&lt;br&gt;&lt;br&gt;infective endocarditis prophylaxis is recommended only for specific oral and dental procedures in patients with specific cardiac conditions | an increase in glucocorticoid dose is recommended in &lt;u&gt;patients at risk of adrenal crisis&lt;/u&gt; (including patients on chronic glucocorticoids [eg prednisolone 5 mg or more daily for more than 3 weeks]); seek advice from the patient’s medical practitioner&lt;br&gt;&lt;br&gt;risk of triggering medication-related osteonecrosis of the jaw (MRONJ) may be increased for patients taking certain medications |

![Table 13.29](L5.2 Haematology 2 WBC_figures/img_322ad9eba1dad813.webp)</text>
    <formatted_text>*Therapeutic Guidelines – Oral and Dental v4 2026*

#### Minimally Invasive Procedures: Dental Restorations Requiring Local Anaesthetic or Closed (Nonsurgical) Root Canal Procedure

- Bleeding risk considerations: unlikely to cause prolonged bleeding if local infiltration alone is used; if an inferior alveolar nerve block is required, see Table 13.30 for considerations to minimise risk
- Antibiotic prophylaxis: surgical antibiotic prophylaxis is not indicated; infective endocarditis prophylaxis is not indicated
- Other considerations: an increase in glucocorticoid dose is recommended for patients at risk of adrenal crisis (including patients on chronic glucocorticoids [e.g. prednisolone 5 mg or more daily for more than 3 weeks]); seek advice from the patient's medical practitioner

#### Invasive Procedures: Tooth Extraction, Periodontal Surgery, Biopsies, Implant Placement, Subgingival Debridement

- Bleeding risk considerations: prolonged bleeding is likely with invasive procedures; see Table 13.30 for considerations to minimise risk
- Antibiotic prophylaxis: for patients **without profound immune compromise**, surgical antibiotic prophylaxis is not indicated for most dental procedures (see Table 13.12); for patients **with profound immune compromise**, consider (with the patient's medical team) whether surgical antibiotic prophylaxis is appropriate; infective endocarditis prophylaxis is recommended only for specific oral and dental procedures in patients with specific cardiac conditions
- Other considerations: an increase in glucocorticoid dose is recommended in patients at risk of adrenal crisis (including patients on chronic glucocorticoids [e.g. prednisolone 5 mg or more daily for more than 3 weeks]); seek advice from the patient's medical practitioner; risk of triggering medication-related osteonecrosis of the jaw (MRONJ) may be increased for patients taking certain medications</formatted_text>
    <images>
      <img order="0" bbox="99,351,905,799" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L5.2 Haematology 2 WBC_figures/img_322ad9eba1dad813.webp" caption="Table 13.29">
        <description>A clinical guideline table detailing dental implications for minimally invasive and invasive procedures. It is organized into columns for bleeding risk, antibiotic prophylaxis, and other considerations, with specific text highlighted in yellow (procedure types) and circled in red (adrenal crisis warnings).</description>
      </img>
    </images>
  </page>
  <page number="74">
    <text># DENTAL IMPLICATIONS

**Therapeutic Guidelines – Oral and Dental v4 2026**

For **dental procedures that do not warrant an increase in glucocorticoid dosing** (see Table 13.29), patients must take their usual glucocorticoid dose on the day of the dental procedure.

For **dental restorations requiring local anaesthetic, closed (nonsurgical) root canal procedures, or any invasive procedures**, an increase in glucocorticoid dose is recommended to minimise the risk of precipitating adrenal crisis. Patients may have a written action plan addressing the need for periprocedural dose increases; if not, seek advice from the patient’s medical practitioner on glucocorticoid dosing adjustment. Advice for medical practitioners is available in Adrenal insufficiency and Adrenocortical suppression. Usually, the patient’s regular glucocorticoid dose is doubled on the morning of the dental procedure (and in some situations, for up to 48 hours postoperatively). Dental practitioners should consult the patient’s medical practitioner when a dose increase is required, to ensure all clinicians involved in the patient’s care can consider the impact of any proposed short-term changes to their glucocorticoid regimen. Seek endocrinologist advice for patients at risk of adrenal crisis who are undergoing general anaesthetic, sedation or fasting.

Perform dental treatment in the morning so that if an adrenal crisis occurs, symptoms present while the patient is awake. After dental treatment, ensure the patient remains in the care of a responsible adult for the rest of the day, and the carer remains in contact with the patient for the following 2 to 3 days. Advise the patient and the carer to seek urgent medical attention if the patient experiences symptoms of adrenal crisis.</text>
    <formatted_text>*Therapeutic Guidelines – Oral and Dental v4 2026*

#### Glucocorticoid Dosing Around Dental Procedures

For **dental procedures that do not warrant an increase in glucocorticoid dosing** (see Table 13.29), patients must take their usual glucocorticoid dose on the day of the dental procedure.

For **dental restorations requiring local anaesthetic, closed (nonsurgical) root canal procedures, or any invasive procedures**, an increase in glucocorticoid dose is recommended to minimise the risk of precipitating adrenal crisis. Patients may have a written action plan addressing the need for periprocedural dose increases; if not, seek advice from the patient's medical practitioner on glucocorticoid dosing adjustment. Usually, the patient's regular glucocorticoid dose is doubled on the morning of the dental procedure (and in some situations, for up to 48 hours postoperatively). Dental practitioners should consult the patient's medical practitioner when a dose increase is required, to ensure all clinicians involved in the patient's care can consider the impact of any proposed short-term changes to their glucocorticoid regimen. Seek endocrinologist advice for patients at risk of adrenal crisis who are undergoing general anaesthetic, sedation or fasting.

#### Post-Procedural Care

Perform dental treatment in the morning so that if an adrenal crisis occurs, symptoms present while the patient is awake. After dental treatment, ensure the patient remains in the care of a responsible adult for the rest of the day, and the carer remains in contact with the patient for the following 2 to 3 days. Advise the patient and the carer to seek urgent medical attention if the patient experiences symptoms of adrenal crisis.</formatted_text>
  </page>
  <page number="75">
    <text>DENTAL IMPLICATIONS

**\*Therapeutic Guidelines – Oral and Dental v4 2026**

Surgery

• Renal dialysis [MM]
    • Drug doses may require reduction
    • Haemodialysis: treat on non-dialysis days (heparinisation)
    • Bleeding tendency, anaemia, infection tendency...
    • (topic of another lecture: *Renal Disease*)</text>
    <formatted_text>*Therapeutic Guidelines – Oral and Dental v4 2026*

#### Renal Dialysis [MM]

- Drug doses may require reduction
- Haemodialysis: treat on non-dialysis days (heparinisation)
- Bleeding tendency, anaemia, infection tendency...
- (Topic of another lecture: *Renal Disease*)</formatted_text>
  </page>
  <page number="76">
    <text>DENTAL IMPLICATIONS

Spread

• Susceptibility to infection $\rightarrow$ infection control protocols

• Transfusions: screened for BBVs

• Immunocompromise/immunosuppression = may be on systemic antifungal (e.g. fluconazole), antiviral (e.g. valaciclovir), antibiotics (e.g. sulfamethoxazole/trimethoprim)

• Predisposed to oral candida, herpes simplex, VZV, etc</text>
    <formatted_text>- Susceptibility to infection → infection control protocols
- Transfusions: screened for BBVs
- Immunocompromise/immunosuppression = may be on systemic antifungal (e.g. fluconazole), antiviral (e.g. valaciclovir), antibiotics (e.g. sulfamethoxazole/trimethoprim)
- Predisposed to oral candida, herpes simplex, VZV, etc</formatted_text>
  </page>
  <page number="77">
    <text>**QUESTIONS?**
Jeeyun.leung@uwa.edu.au

![](L5.2 Haematology 2 WBC_figures/img_12b1a9baf52a88e5.webp)</text>
    <formatted_text>**QUESTIONS?**

Jeeyun.leung@uwa.edu.au</formatted_text>
    <images>
      <img order="0" bbox="22,168,552,831" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L5.2 Haematology 2 WBC_figures/img_12b1a9baf52a88e5.webp">
        <description>A micrograph of a blood smear showing numerous red blood cells and several white blood cells with distinct multi-lobed nuclei, characteristic of neutrophils.</description>
      </img>
    </images>
  </page>
  <page number="78" origin="cases">
    <text>## Case: Patient with polycythemia vera and aquagenic pruritus

### Question

**Scenario:** A male patient with polycythemia vera and a history of aquagenic pruritus presents for dental treatment.

**What's shown:** The patient's medical history of aquagenic pruritus, a condition characterized by itchy skin following contact with water.

**Consider:** How the patient's specific condition affects the delivery and management of dental treatment.

### Answer

**Observations:**
- The patient has polycythemia vera.
- The patient experiences aquagenic pruritus (itchy skin following contact with water), which can be a chief complaint and is considered unbearable in about 15% of cases with this symptom.

**Reasoning:** Dental treatment typically involves a lot of water. For a patient with aquagenic pruritus, exposure to water can trigger severe itching, making standard dental procedures highly problematic and uncomfortable for the patient. 

**Outcome:** The dental team had to take it quite easy and carefully modify the treatment approach to minimize the patient's exposure to water.

**Takeaway:** Aquagenic pruritus, a symptom associated with polycythemia vera, is triggered by water contact, requiring the dental team to carefully manage and minimize water use during dental procedures.

## Case: Skull radiograph showing multiple myeloma features

### Question

**Scenario:** A PA skull radiograph is presented to illustrate the skeletal manifestations of multiple myeloma.

**What's shown:** A PA skull view revealing multiple punched-out radiolucencies in the skull and a right-sided mandibular pathological fracture.

**Consider:** Identify the radiographic findings and explain the underlying pathophysiology and clinical implications for the jaws and systemic health.


### Answer

**Observations:**
- Multiple punched-out radiolucencies in the skull.
- A right-sided mandibular pathological fracture.

**Reasoning:** In multiple myeloma, neoplastic proliferation of plasma cells in the bone marrow releases cytokines that lead to osteolysis and bone destruction. This process causes mandibular lesions in about 5 to 14% of patients, which can present clinically as dental mobility, pain, paresthesia, soft tissue swellings, and pathological jaw fractures. Additionally, the proliferation can cause suppression of hemopoiesis and bone marrow replacement, leading to anemia, increased infection risk, and bleeding tendencies. Defective immunoglobulins can also cause plasma hyperviscosity, renal failure, and neurological sequelae.

**Takeaway:** Multiple myeloma causes osteolytic bone destruction via cytokine release, which can present radiographically as multiple punched-out skull radiolucencies and mandibular pathological fractures, alongside systemic complications from bone marrow suppression.</text>
    <formatted_text>## Case: Patient with polycythemia vera and aquagenic pruritus

### Question

**Scenario:** A male patient with polycythemia vera and a history of aquagenic pruritus presents for dental treatment.

**What's shown:** The patient's medical history of aquagenic pruritus, a condition characterized by itchy skin following contact with water.

**Consider:** How the patient's specific condition affects the delivery and management of dental treatment.

### Answer

**Observations:**
- The patient has polycythemia vera.
- The patient experiences aquagenic pruritus (itchy skin following contact with water), which can be a chief complaint and is considered unbearable in about 15% of cases with this symptom.

**Reasoning:** Dental treatment typically involves a lot of water. For a patient with aquagenic pruritus, exposure to water can trigger severe itching, making standard dental procedures highly problematic and uncomfortable for the patient. 

**Outcome:** The dental team had to take it quite easy and carefully modify the treatment approach to minimize the patient's exposure to water.

**Takeaway:** Aquagenic pruritus, a symptom associated with polycythemia vera, is triggered by water contact, requiring the dental team to carefully manage and minimize water use during dental procedures.

## Case: Skull radiograph showing multiple myeloma features

### Question

**Scenario:** A PA skull radiograph is presented to illustrate the skeletal manifestations of multiple myeloma.

**What's shown:** A PA skull view revealing multiple punched-out radiolucencies in the skull and a right-sided mandibular pathological fracture.

**Consider:** Identify the radiographic findings and explain the underlying pathophysiology and clinical implications for the jaws and systemic health.


![](L5.2 Haematology 2 WBC_cases_attachments/img_c4b29a91cbf182ad.webp)
![](L5.2 Haematology 2 WBC_cases_attachments/img_2a65017d254e23f9.webp)
### Answer

**Observations:**
- Multiple punched-out radiolucencies in the skull.
- A right-sided mandibular pathological fracture.

**Reasoning:** In multiple myeloma, neoplastic proliferation of plasma cells in the bone marrow releases cytokines that lead to osteolysis and bone destruction. This process causes mandibular lesions in about 5 to 14% of patients, which can present clinically as dental mobility, pain, paresthesia, soft tissue swellings, and pathological jaw fractures. Additionally, the proliferation can cause suppression of hemopoiesis and bone marrow replacement, leading to anemia, increased infection risk, and bleeding tendencies. Defective immunoglobulins can also cause plasma hyperviscosity, renal failure, and neurological sequelae.

**Takeaway:** Multiple myeloma causes osteolytic bone destruction via cytokine release, which can present radiographically as multiple punched-out skull radiolucencies and mandibular pathological fractures, alongside systemic complications from bone marrow suppression.</formatted_text>
    <heading_path>Case: Patient with polycythemia vera and aquagenic pruritus</heading_path>
    <images>
      <img order="0" type="figure" path="L5.2 Haematology 2 WBC_figures/img_c4b29a91cbf182ad.webp" media="frame" source="slide" page="53" timestamp="00:40:53">
        <description>Shows multiple punchout radiolucencies A radiograph of a human skull in an anterior-posterior view, showing the cranium, orbits, nasal cavity, and mandible. The image illustrates multiple small, dark circular spots scattered across the frontal bone (forehead area), which are characteristic punched-out radiolucencies.</description>
      </img>
      <img order="1" type="photo" path="L5.2 Haematology 2 WBC_figures/img_2a65017d254e23f9.webp" media="frame" source="slide" page="54" timestamp="00:42:00">
        <description>Clinical photo showing the intraoral view of a maxillary arch with a large, erythematous swelling on the hard palate adjacent to the upper teeth.</description>
      </img>
    </images>
  </page>
  <footnotes>[^1]: Original PDF page 1: [[L5.2 Haematology 2 WBC.pdf#page=1|L5.2 Haematology 2 WBC, p.1]]
[^2]: Original PDF page 2: [[L5.2 Haematology 2 WBC.pdf#page=2|L5.2 Haematology 2 WBC, p.2]]
[^3]: Original PDF page 3: [[L5.2 Haematology 2 WBC.pdf#page=3|L5.2 Haematology 2 WBC, p.3]]
[^4]: Original PDF page 4: [[L5.2 Haematology 2 WBC.pdf#page=4|L5.2 Haematology 2 WBC, p.4]]
[^5]: Original PDF page 5: [[L5.2 Haematology 2 WBC.pdf#page=5|L5.2 Haematology 2 WBC, p.5]]
[^6]: Original PDF page 6: [[L5.2 Haematology 2 WBC.pdf#page=6|L5.2 Haematology 2 WBC, p.6]]
[^7]: Original PDF page 7: [[L5.2 Haematology 2 WBC.pdf#page=7|L5.2 Haematology 2 WBC, p.7]]
[^8]: Original PDF page 8: [[L5.2 Haematology 2 WBC.pdf#page=8|L5.2 Haematology 2 WBC, p.8]]
[^9]: Original PDF page 9: [[L5.2 Haematology 2 WBC.pdf#page=9|L5.2 Haematology 2 WBC, p.9]]
[^10]: Original PDF page 10: [[L5.2 Haematology 2 WBC.pdf#page=10|L5.2 Haematology 2 WBC, p.10]]
[^11]: Original PDF page 11: [[L5.2 Haematology 2 WBC.pdf#page=11|L5.2 Haematology 2 WBC, p.11]]
[^12]: Original PDF page 12: [[L5.2 Haematology 2 WBC.pdf#page=12|L5.2 Haematology 2 WBC, p.12]]
[^13]: Original PDF page 13: [[L5.2 Haematology 2 WBC.pdf#page=13|L5.2 Haematology 2 WBC, p.13]]
[^14]: Original PDF page 14: [[L5.2 Haematology 2 WBC.pdf#page=14|L5.2 Haematology 2 WBC, p.14]]
[^15]: Original PDF page 15: [[L5.2 Haematology 2 WBC.pdf#page=15|L5.2 Haematology 2 WBC, p.15]]
[^16]: Original PDF page 16: [[L5.2 Haematology 2 WBC.pdf#page=16|L5.2 Haematology 2 WBC, p.16]]
[^17]: Original PDF page 17: [[L5.2 Haematology 2 WBC.pdf#page=17|L5.2 Haematology 2 WBC, p.17]]
[^18]: Original PDF page 18: [[L5.2 Haematology 2 WBC.pdf#page=18|L5.2 Haematology 2 WBC, p.18]]
[^19]: Original PDF page 19: [[L5.2 Haematology 2 WBC.pdf#page=19|L5.2 Haematology 2 WBC, p.19]]
[^20]: Original PDF page 20: [[L5.2 Haematology 2 WBC.pdf#page=20|L5.2 Haematology 2 WBC, p.20]]
[^21]: Original PDF page 21: [[L5.2 Haematology 2 WBC.pdf#page=21|L5.2 Haematology 2 WBC, p.21]]
[^22]: Original PDF page 22: [[L5.2 Haematology 2 WBC.pdf#page=22|L5.2 Haematology 2 WBC, p.22]]
[^23]: Original PDF page 23: [[L5.2 Haematology 2 WBC.pdf#page=23|L5.2 Haematology 2 WBC, p.23]]
[^24]: Original PDF page 24: [[L5.2 Haematology 2 WBC.pdf#page=24|L5.2 Haematology 2 WBC, p.24]]
[^25]: Original PDF page 25: [[L5.2 Haematology 2 WBC.pdf#page=25|L5.2 Haematology 2 WBC, p.25]]
[^26]: Original PDF page 26: [[L5.2 Haematology 2 WBC.pdf#page=26|L5.2 Haematology 2 WBC, p.26]]
[^27]: Original PDF page 27: [[L5.2 Haematology 2 WBC.pdf#page=27|L5.2 Haematology 2 WBC, p.27]]
[^28]: Original PDF page 28: [[L5.2 Haematology 2 WBC.pdf#page=28|L5.2 Haematology 2 WBC, p.28]]
[^29]: Original PDF page 29: [[L5.2 Haematology 2 WBC.pdf#page=29|L5.2 Haematology 2 WBC, p.29]]
[^30]: Original PDF page 30: [[L5.2 Haematology 2 WBC.pdf#page=30|L5.2 Haematology 2 WBC, p.30]]
[^31]: Original PDF page 31: [[L5.2 Haematology 2 WBC.pdf#page=31|L5.2 Haematology 2 WBC, p.31]]
[^32]: Original PDF page 32: [[L5.2 Haematology 2 WBC.pdf#page=32|L5.2 Haematology 2 WBC, p.32]]
[^33]: Original PDF page 33: [[L5.2 Haematology 2 WBC.pdf#page=33|L5.2 Haematology 2 WBC, p.33]]
[^34]: Original PDF page 34: [[L5.2 Haematology 2 WBC.pdf#page=34|L5.2 Haematology 2 WBC, p.34]]
[^35]: Original PDF page 35: [[L5.2 Haematology 2 WBC.pdf#page=35|L5.2 Haematology 2 WBC, p.35]]
[^36]: Original PDF page 36: [[L5.2 Haematology 2 WBC.pdf#page=36|L5.2 Haematology 2 WBC, p.36]]
[^37]: Original PDF page 37: [[L5.2 Haematology 2 WBC.pdf#page=37|L5.2 Haematology 2 WBC, p.37]]
[^38]: Original PDF page 38: [[L5.2 Haematology 2 WBC.pdf#page=38|L5.2 Haematology 2 WBC, p.38]]
[^39]: Original PDF page 39: [[L5.2 Haematology 2 WBC.pdf#page=39|L5.2 Haematology 2 WBC, p.39]]
[^40]: Original PDF page 40: [[L5.2 Haematology 2 WBC.pdf#page=40|L5.2 Haematology 2 WBC, p.40]]
[^41]: Original PDF page 41: [[L5.2 Haematology 2 WBC.pdf#page=41|L5.2 Haematology 2 WBC, p.41]]
[^42]: Original PDF page 42: [[L5.2 Haematology 2 WBC.pdf#page=42|L5.2 Haematology 2 WBC, p.42]]
[^43]: Original PDF page 43: [[L5.2 Haematology 2 WBC.pdf#page=43|L5.2 Haematology 2 WBC, p.43]]
[^44]: Original PDF page 44: [[L5.2 Haematology 2 WBC.pdf#page=44|L5.2 Haematology 2 WBC, p.44]]
[^45]: Original PDF page 45: [[L5.2 Haematology 2 WBC.pdf#page=45|L5.2 Haematology 2 WBC, p.45]]
[^46]: Original PDF page 46: [[L5.2 Haematology 2 WBC.pdf#page=46|L5.2 Haematology 2 WBC, p.46]]
[^47]: Original PDF page 47: [[L5.2 Haematology 2 WBC.pdf#page=47|L5.2 Haematology 2 WBC, p.47]]
[^48]: Original PDF page 48: [[L5.2 Haematology 2 WBC.pdf#page=48|L5.2 Haematology 2 WBC, p.48]]
[^49]: Original PDF page 49: [[L5.2 Haematology 2 WBC.pdf#page=49|L5.2 Haematology 2 WBC, p.49]]
[^50]: Original PDF page 50: [[L5.2 Haematology 2 WBC.pdf#page=50|L5.2 Haematology 2 WBC, p.50]]
[^51]: Original PDF page 51: [[L5.2 Haematology 2 WBC.pdf#page=51|L5.2 Haematology 2 WBC, p.51]]
[^52]: Original PDF page 52: [[L5.2 Haematology 2 WBC.pdf#page=52|L5.2 Haematology 2 WBC, p.52]]
[^53]: Original PDF page 53: [[L5.2 Haematology 2 WBC.pdf#page=53|L5.2 Haematology 2 WBC, p.53]]
[^54]: Original PDF page 54: [[L5.2 Haematology 2 WBC.pdf#page=54|L5.2 Haematology 2 WBC, p.54]]
[^55]: Original PDF page 55: [[L5.2 Haematology 2 WBC.pdf#page=55|L5.2 Haematology 2 WBC, p.55]]
[^56]: Original PDF page 56: [[L5.2 Haematology 2 WBC.pdf#page=56|L5.2 Haematology 2 WBC, p.56]]
[^57]: Original PDF page 57: [[L5.2 Haematology 2 WBC.pdf#page=57|L5.2 Haematology 2 WBC, p.57]]
[^58]: Original PDF page 58: [[L5.2 Haematology 2 WBC.pdf#page=58|L5.2 Haematology 2 WBC, p.58]]
[^59]: Original PDF page 59: [[L5.2 Haematology 2 WBC.pdf#page=59|L5.2 Haematology 2 WBC, p.59]]
[^60]: Original PDF page 60: [[L5.2 Haematology 2 WBC.pdf#page=60|L5.2 Haematology 2 WBC, p.60]]
[^61]: Original PDF page 61: [[L5.2 Haematology 2 WBC.pdf#page=61|L5.2 Haematology 2 WBC, p.61]]
[^62]: Original PDF page 62: [[L5.2 Haematology 2 WBC.pdf#page=62|L5.2 Haematology 2 WBC, p.62]]
[^63]: Original PDF page 63: [[L5.2 Haematology 2 WBC.pdf#page=63|L5.2 Haematology 2 WBC, p.63]]
[^64]: Original PDF page 64: [[L5.2 Haematology 2 WBC.pdf#page=64|L5.2 Haematology 2 WBC, p.64]]
[^65]: Original PDF page 65: [[L5.2 Haematology 2 WBC.pdf#page=65|L5.2 Haematology 2 WBC, p.65]]
[^66]: Original PDF page 66: [[L5.2 Haematology 2 WBC.pdf#page=66|L5.2 Haematology 2 WBC, p.66]]
[^67]: Original PDF page 67: [[L5.2 Haematology 2 WBC.pdf#page=67|L5.2 Haematology 2 WBC, p.67]]
[^68]: Original PDF page 68: [[L5.2 Haematology 2 WBC.pdf#page=68|L5.2 Haematology 2 WBC, p.68]]
[^69]: Original PDF page 69: [[L5.2 Haematology 2 WBC.pdf#page=69|L5.2 Haematology 2 WBC, p.69]]
[^70]: Original PDF page 70: [[L5.2 Haematology 2 WBC.pdf#page=70|L5.2 Haematology 2 WBC, p.70]]
[^71]: Original PDF page 71: [[L5.2 Haematology 2 WBC.pdf#page=71|L5.2 Haematology 2 WBC, p.71]]
[^72]: Original PDF page 72: [[L5.2 Haematology 2 WBC.pdf#page=72|L5.2 Haematology 2 WBC, p.72]]
[^73]: Original PDF page 73: [[L5.2 Haematology 2 WBC.pdf#page=73|L5.2 Haematology 2 WBC, p.73]]
[^74]: Original PDF page 74: [[L5.2 Haematology 2 WBC.pdf#page=74|L5.2 Haematology 2 WBC, p.74]]
[^75]: Original PDF page 75: [[L5.2 Haematology 2 WBC.pdf#page=75|L5.2 Haematology 2 WBC, p.75]]
[^76]: Original PDF page 76: [[L5.2 Haematology 2 WBC.pdf#page=76|L5.2 Haematology 2 WBC, p.76]]
[^77]: Original PDF page 77: [[L5.2 Haematology 2 WBC.pdf#page=77|L5.2 Haematology 2 WBC, p.77]]</footnotes>
</document>
